Chapter review

Must know

• MDD Diagnostic CriteriaDiagnostic Timeline and Threshold: Diagnosis requires 5 or more of 9 symptoms present nearly every day during the same 2-week period, representing a distinct change from previous functioning.

  • Diagnostic Timeline and Threshold: Diagnosis requires 5 or more of 9 symptoms present nearly every day during the same 2-week period, representing a distinct change from previous functioning.
  • Core Symptom Requirement: At least 1 of the 5 required symptoms must be either depressed mood or anhedonia (loss of interest or pleasure).
  • Key Mnemonic: The SIG E CAPS mnemonic summarizes the 9 diagnostic criteria: Sleep changes, Interest loss, Guilt or worthlessness, Energy loss, Concentration impairment, Appetite or weight changes, Psychomotor retardation or agitation, and Suicidal ideation.
  • Epidemiology Metrics: Lifetime prevalence is 12 percent, with a 2 to 1 female-to-male ratio. Prevalence in young adults aged 18 to 29 is 3 times higher than in adults over 60, with a mean onset between 20 and 35 years.
  • Heritability and Inpatient Risk: Heritability is 40 percent with a 2 to 4 times higher risk in first-degree relatives. Medical inpatients carry a 15 percent higher risk of major depressive disorder than the general population.
  • Prognosis and Bipolar Conversion: Untreated episodes last 6 to 13 months, and 50 percent of hospitalized patients recover within 1 year. Crucially, 5 to 10 percent of patients initially diagnosed with major depressive disorder develop a manic episode 6 to 10 years later.
• Core Symptom Logic and ScreeningThe initial evaluation relies on screening for depressed mood and anhedonia.

  • The initial evaluation relies on screening for depressed mood and anhedonia.
  • Using the PHQ-2 screening tool, if a patient denies both depressed mood and loss of interest or pleasure, major depressive disorder is ruled out.
  • A patient can deny feeling sad, down, or blue, but if anhedonia is present along with 4 other qualifying criteria, the full diagnostic threshold for a major depressive episode is satisfied.
• SIG E CAPS Criteria BreakdownSleep: Insomnia or hypersomnia where sleep fails to feel restorative.

  • Sleep: Insomnia or hypersomnia where sleep fails to feel restorative.
  • Interest: Depressed mood or anhedonia. Mood often shows a marked diurnal variation, presenting worst in the morning and improving as the day progresses. In children and adolescents, irritability serves as a diagnostic depression equivalent.
  • Guilt: Feelings of worthlessness or excessive, inappropriate, and potentially delusional guilt.
  • Energy: Severe fatigue, lack of ambition, or feeling physically drained.
  • Concentration: Diminished ability to think clearly, indecisiveness, or memory complaints that can mimic pseudodementia in older adults.
  • Appetite: Significant weight loss or weight gain, loss of food enjoyment, or failure to achieve expected weight gain in pediatric patients.
• Clinical SignpostsScreen every patient presenting with depressive symptoms for a past history of mania or hypomania to rule out bipolar disorder before starting treatment.

  • Screen every patient presenting with depressive symptoms for a past history of mania or hypomania to rule out bipolar disorder before starting treatment.
  • Continuously assess for suicidal ideation and active plans. Passive thoughts of death are most common, but active intent requires immediate safety planning and potential inpatient admission.
  • Bereavement is not an automatic exclusion for a major depressive episode, nor is altered mood from bereavement a diagnostic criterion itself. Clinical judgment is required to distinguish normal grief from a major depressive episode.

  Board trap. Bereavement is not an automatic exclusion for a major depressive episode, nor is altered mood from bereavement a diagnostic criterion itself. Clinical judgment is required to distinguish normal grief from a major depressive episode.

  Safety. Continuously assess for suicidal ideation and active plans. Passive thoughts of death are most common, but active intent requires immediate safety planning and potential inpatient admission.

• Epidemiology and Clinical CoursePrevalence: Lifetime prevalence is 12 percent. Women are affected at twice the rate of men.

  • Prevalence: Lifetime prevalence is 12 percent. Women are affected at twice the rate of men.
  • Age Dynamics: Prevalence in adults aged 18 to 29 is 3 times higher than in adults over age 60. The mean age of onset is between 20 and 35 years.
  • Medical Comorbidity: Medical inpatients have a 15 percent higher prevalence of major depressive disorder than the general population. Common psychiatric comorbidities include ADHD, anxiety disorders, PTSD, conduct disorder, learning disabilities, and substance use disorders.
  • Genetics: Heritability is estimated at 40 percent. First-degree relatives face a 2 to 4 times higher risk than the general population.
  • Prognosis: Untreated episodes last 6 to 13 months. Following hospitalization, 50 percent of patients recover within 1 year. Between 5 and 10 percent of patients with major depressive disorder will experience a manic episode 6 to 10 years after their initial depressive event.
• Rating Scales and Disability MetricsPHQ-9: Scores of 1 to 4 reflect minimal depression, 5 to 9 reflect mild depression, 10 to 14 reflect moderate depression, 15 to 19 reflect moderately severe depression, and 20 to 27 reflect severe depression.

  • PHQ-9: Scores of 1 to 4 reflect minimal depression, 5 to 9 reflect mild depression, 10 to 14 reflect moderate depression, 15 to 19 reflect moderately severe depression, and 20 to 27 reflect severe depression.
• Differential DiagnosisMedical and Substance Rule-Outs: Always rule out direct physical causes such as hypothyroidism, cerebrovascular accidents, or Parkinson's disease, as well as substance-induced mood changes from alcohol, stimulants, or prescribed medications like steroids.

  • Medical and Substance Rule-Outs: Always rule out direct physical causes such as hypothyroidism, cerebrovascular accidents, or Parkinson's disease, as well as substance-induced mood changes from alcohol, stimulants, or prescribed medications like steroids.
  • Bipolar Spectrum: Differentiate unipolar depression from bipolar I disorder, bipolar II disorder, and cyclothymic disorder.
• Which of the following statements is false regarding the diagnosis of major depression?A. More likely to occur in men than women

  • A. More likely to occur in men than women
  • B. Higher prevalence for whites than blacks
  • C. Lifetime prevalence is 12%
  • D. Risk factors include genetics and low education
• Which of the following is not a DSM-5-TR criterion for major depressive episode?B. Loss of food enjoyment

  • B. Loss of food enjoyment
  • D. Altered mood associated with bereavement
• Mnemonic: SIG E CAPSMajor depressive disorder diagnosis requires at least 5 of 9 criteria present nearly every day during a minimum 2-week timeline, with at least 1 core criterion being depressed mood or anhedonia.

  • Major depressive disorder diagnosis requires at least 5 of 9 criteria present nearly every day during a minimum 2-week timeline, with at least 1 core criterion being depressed mood or anhedonia.
  • The lifetime prevalence of major depressive disorder is 12%, with a 2-fold higher risk in women compared to men, and a 3-times higher prevalence in adults aged 18 to 29 compared to those over 60.
  • First-line screening utilizes the PHQ-2 (evaluating depressed mood and anhedonia) followed by the PHQ-9, where severity is scored as 5 to 9 for mild, 10 to 14 for moderate, 15 to 19 for moderately severe, and 20 to 27 for severe depression.
  • The SIG E CAPS mnemonic memory hook links the Latin prescription direction "sig" with "energy capsules" to systematically recall all 8 symptom domains.
  • Medical inpatients carry a 15% higher risk of major depressive disorder than the general population, and first-degree relatives have a 2-to-4 times higher genetic risk with a 40% heritability rate.
  • Screening for prior manic or hypomanic episodes is mandatory before confirming unipolar major depressive disorder or initiating psychotropics, as 5% to 10% of patients diagnosed with depression experience a manic episode 6 to 10 years later.

  Board trap. Assuming a patient cannot have major depressive disorder if they deny feeling sad or blue is a common error; meeting criteria through anhedonia plus 4 other symptoms satisfies the diagnosis.

  Safety. Screening for prior manic or hypomanic episodes is mandatory before confirming unipolar major depressive disorder or initiating psychotropics, as 5% to 10% of patients diagnosed with depression experience a manic episode 6 to 10 years later.

• Breakdown of the SIG E CAPS Symptom DomainsS - Sleep: Disturbance presenting as insomnia (difficulty falling asleep, middle awakening, or early morning awakening) or non-restful hypersomnia where the patient sleeps excessively but wakes unrefreshed.

  • S - Sleep: Disturbance presenting as insomnia (difficulty falling asleep, middle awakening, or early morning awakening) or non-restful hypersomnia where the patient sleeps excessively but wakes unrefreshed.
  • G - Guilt: Pathologic feelings of worthlessness, self-reproach, or excessive and inappropriate guilt that may reach near-delusional or frank delusional proportions.
  • E - Energy: Chronic fatigue, loss of energy, or a total lack of ambition to complete routine tasks.
  • C - Concentration: Diminished ability to think, concentrate, or make simple decisions. Patients frequently report inability to finish reading a single page and may express fear that they are developing dementia or organic cognitive decline.
  • A - Appetite: Unintended weight loss or weight gain, or significant decrease or increase in appetite. It also includes loss of food enjoyment. In pediatric patients, this criterion includes failure to achieve expected developmental weight gains.
  • S - Suicide: Recurrent thoughts of death, passive suicidal ideation without a plan (the most common presentation), active suicidal ideation with a plan or intent, or a definitive suicide attempt.
• Diagnostic Timelines and Differential SignpostsFirst-line assessment: Administer the PHQ-2 screening tool. Because depressed mood or anhedonia must be present to establish the diagnosis, a negative PHQ-2 effectively rules out a major depressive episode. If positive, proceed immediately to the PHQ-9.

  • First-line assessment: Administer the PHQ-2 screening tool. Because depressed mood or anhedonia must be present to establish the diagnosis, a negative PHQ-2 effectively rules out a major depressive episode. If positive, proceed immediately to the PHQ-9.

  Board trap. Confusing bereavement with a major depressive episode. Uncomplicated grief fluctuates in waves tied to thoughts of the deceased, whereas major depressive disorder involves persistent unremitting depressed mood and pervasive self-loathing. Bereavement alone is not a DSM-5-TR crite

  Safety. Always rule out bipolar disorder, substance-induced mood disruption, and general medical conditions (such as hypothyroidism or cerebrovascular accidents) before confirming unipolar major depressive disorder. Initiating antidepressant monotherapy in unrecognized bipolar disorder c

• Table 8-1: MDD Epidemiology and RiskLifetime prevalence: Major depressive disorder carries a lifetime prevalence of 12%, making it one of the most frequently tested psychiatric conditions on national board certification exams.

  • Lifetime prevalence: Major depressive disorder carries a lifetime prevalence of 12%, making it one of the most frequently tested psychiatric conditions on national board certification exams.
  • Gender risk: Women face a 2 times higher risk for major depressive disorder than men (a 2 to 1 female to male ratio), whereas bipolar I disorder affects men and women equally.
  • Age distribution: Major depressive disorder is primarily a younger person's illness with a mean age of onset between 20 and 35 years. Prevalence in young adults aged 18 to 29 is 3 times higher than in adults over 60 years of age.
  • Medical inpatient risk: Medical inpatients experience a 15% higher risk of major depressive disorder than the general population, highlighting the critical role of screening in consultation-liaison settings.
  • Heritability and genetics: Major depressive disorder has a heritability of approximately 40%. First-degree relatives of affected individuals have a 2 to 4 times higher risk of developing the disorder compared to the general population.
  • High-yield comorbidities: Major depressive disorder frequently co-occurs with non-mood conditions including ADHD, PTSD, anxiety disorders, conduct disorder, learning disabilities, and substance use disorders.
• Clinical Settings, Comorbidities, and SignpostsThe initial step in managing major depressive disorder is establishing and maintaining a therapeutic alliance. Diagnostic confirmation requires identifying at least 5 SIGECAPS criteria for a minimum duration of 2 weeks, with at least one required cardinal symptom being depressed

  • **Safety alert**: Medical inpatients carry a 15% higher risk of **major depressive disorder** than the general population.
  • **Board trap**: Exam items frequently present patients with non-mood primary conditions and ask if depression screening is necessary.
  • **Major depressive disorder** has high comorbidity with non-mood psychiatric conditions such as **ADHD**, **PTSD**, anxiety disorders, conduct disorder, learning disabilities, and **substance use disorders**.
  • Never attribute depressive symptoms solely to a co-occurring disorder without formally screening with standardized tools like the **PHQ-9**.

  Board trap. Exam items frequently present patients with non-mood primary conditions and ask if depression screening is necessary. Major depressive disorder has high comorbidity with non-mood psychiatric conditions such as ADHD, PTSD, anxiety disorders, conduct disorder, learning disabilities

  Safety. Medical inpatients carry a 15% higher risk of major depressive disorder than the general population. On inpatient consultation-liaison units, always evaluate medical inpatients presenting with apathy, fatigue, or low mood for active suicidal ideation and rule out organic medical

• Course and PrognosisUntreated major depressive episodes typically last 6 to 13 months, with 50 percent of hospitalized patients recovering within the first year.

  • Untreated major depressive episodes typically last 6 to 13 months, with 50 percent of hospitalized patients recovering within the first year.
  • A unipolar depression diagnosis carries a 5 to 10 percent risk of converting to Bipolar Disorder, as patients develop a manic episode 6 to 10 years after their initial depressive event.
  • Recurrence is common: 20 percent of patients experience a relapse within 6 months of remission, and 50 to 85 percent suffer at least one lifetime recurrence.
  • Continuation phase treatment requires keeping the patient on full therapeutic antidepressant doses for 4 to 9 months post-remission to prevent immediate relapse.
  • Maintenance phase pharmacotherapy is indicated indefinitely for patients with 3 or more lifetime major depressive episodes or severe co-occurring risk factors.
  • Discontinuation of antidepressant therapy requires a 6-week gradual taper to avoid withdrawal symptoms, followed by a mandatory clinic evaluation at 2 months post-cessation.
• Recurrence Risk Factors and Longitudinal DynamicsA history of 3 or more prior major depressive episodes.

  • A history of 3 or more prior major depressive episodes.
  • Persistent residual mild depressive symptoms rather than complete symptom remission.
  • High severity of past episodes, including past suicidal attempts or psychotic features.
  • Early age of onset, particularly during adolescence or early adulthood.
  • Co-occurring non-affective psychiatric disorders, such as generalized anxiety disorder, panic disorder, ADHD, or substance use disorders.
  • Co-occurring general medical conditions, such as type 1 diabetes mellitus, cerebrovascular accidents, or chronic pain.
• Treatment Phases, Discontinuation, and Follow-UpNever stop medications abruptly. Taper the drug gradually over approximately 6 weeks to prevent antidepressant discontinuation syndrome.

  • Never stop medications abruptly. Taper the drug gradually over approximately 6 weeks to prevent antidepressant discontinuation syndrome.
  • Avoid initiating a taper immediately prior to or during major life stressors, such as starting graduate school, moving, or major holiday periods.
  • Educate the patient and family on early personal warning signs of relapse, such as subtle changes in sleep patterns, social withdrawal, or missed work.
  • Schedule a mandatory follow-up evaluation 2 months after complete cessation of medication to assess for early recurrence during the vulnerable post-discontinuation window.
• Depressive SpecifiersMajor depressive disorder severity specifiers are classified as mild, moderate, moderately severe, and severe using validated tools like the PHQ-9, where scores of 1 to 4 indicate minimal, 5 to 9 mild, 10 to 14 moderate, 15 to 19 moderately severe, and 20 to 27 severe depression.

  • Major depressive disorder severity specifiers are classified as mild, moderate, moderately severe, and severe using validated tools like the PHQ-9, where scores of 1 to 4 indicate minimal, 5 to 9 mild, 10 to 14 moderate, 15 to 19 moderately severe, and 20 to 27 severe depression.
  • With peripartum onset specifier requires mood symptom onset during pregnancy or within the initial 4 weeks following delivery. Interpersonal psychotherapy is preferred for mild to moderate cases, while sertraline or citalopram are preferred SSRIs if pharmacotherapy is necessary.
  • With psychotic features specifier indicates severe depression accompanied by mood-congruent or mood-incongruent delusions or hallucinations, requiring combination therapy with an antidepressant and a second-generation antipsychotic, or electroconvulsive therapy.
  • With anxious distress specifier identifies co-occurring anxiety symptoms during a depressive episode, elevating suicide risk and treatment complexity. Bupropion is not recommended first-line when severe anxiety or panic is prominent.
  • With atypical features specifier features mood reactivity where mood brightens in response to positive events, paired with hypersomnia, hyperphagia or weight gain, leaden paralysis in limbs, and a long-standing pattern of interpersonal rejection sensitivity.
• Severity and Remission SpecifiersWhy boards care: Severity dictates whether non-pharmacologic monotherapy is safe or if immediate psychotropic intervention or hospitalization is required.

  • Why boards care: Severity dictates whether non-pharmacologic monotherapy is safe or if immediate psychotropic intervention or hospitalization is required.
  • Board trap. Selecting psychotherapy monotherapy for severe depression. Psychotherapy alone lacks evidence for severe depression and represents a classic board distractor.
  • Safety alert. Severe depression with a PHQ-9 score of 20 or greater carries a significantly heightened risk for active suicidal ideation and intent, requiring immediate safety risk evaluation and determination of the appropriate care setting.

  Board trap. Board trap. Selecting psychotherapy monotherapy for severe depression. Psychotherapy alone lacks evidence for severe depression and represents a classic board distractor.

  Safety. Safety alert. Severe depression with a PHQ-9 score of 20 or greater carries a significantly heightened risk for active suicidal ideation and intent, requiring immediate safety risk evaluation and determination of the appropriate care setting.

• Peripartum Onset SpecifierWhat it is: Depressive episode occurring during pregnancy or in the immediate postpartum period.

  • What it is: Depressive episode occurring during pregnancy or in the immediate postpartum period.
  • Why boards care: Test writers evaluate your ability to manage maternal mental health safely while balancing fetal and neonatal drug exposure risks.
  • Diagnostic criteria require mood symptom onset during pregnancy or within the first 4 weeks post-delivery. Up to 7% of pregnant women require antidepressant therapy during pregnancy.
  • Board trap. Assuming all psychotropic medications are strictly contraindicated during pregnancy or advising a patient to discontinue effective treatment without weighing relapse risks. Unmanaged maternal depression carries severe maternal and fetal risks.

  Board trap. Board trap. Assuming all psychotropic medications are strictly contraindicated during pregnancy or advising a patient to discontinue effective treatment without weighing relapse risks. Unmanaged maternal depression carries severe maternal and fetal risks.

  Safety. Safety alert. Lithium is classified as Hale lactation risk category L4 and is contraindicated during breastfeeding due to significant infant toxicity risks from renal clearance differences and fluid shifts. Electroconvulsive therapy is safe and highly effective for severe, refrac

• Psychotic Features SpecifierWhat it is: Severe depressive episode accompanied by delusions or hallucinations, which may be mood-congruent, such as guilt, poverty, or severe somatic delusions, or mood-incongruent.

  • What it is: Severe depressive episode accompanied by delusions or hallucinations, which may be mood-congruent, such as guilt, poverty, or severe somatic delusions, or mood-incongruent.
  • Why boards care: Requires immediate combination pharmacotherapy or neuromodulation rather than standard antidepressant monotherapy.
  • Presence of psychotic symptoms during an active severe major depressive episode.
  • First-line approach: First-line treatment mandates a combination of an antidepressant plus a second-generation antipsychotic, such as olanzapine or quetiapine, or electroconvulsive therapy.
  • Board trap. Choosing antidepressant monotherapy or psychotherapy alone for psychotic depression. Psychotherapy alone has zero efficacy for psychotic depression.
  • Safety alert. Psychotic depression is a psychiatric emergency due to extreme suicide risk, command hallucinations, or profound functional incapacity, frequently necessitating inpatient psychiatric admission.

  Board trap. Board trap. Choosing antidepressant monotherapy or psychotherapy alone for psychotic depression. Psychotherapy alone has zero efficacy for psychotic depression.

  Safety. Safety alert. Psychotic depression is a psychiatric emergency due to extreme suicide risk, command hallucinations, or profound functional incapacity, frequently necessitating inpatient psychiatric admission.

• Seasonal Pattern SpecifierWhat it is: Recurrent depressive episodes demonstrating a clear temporal relationship between onset and a specific time of year.

  • What it is: Recurrent depressive episodes demonstrating a clear temporal relationship between onset and a specific time of year.
  • Why boards care: Tests knowledge of non-pharmacologic chronotherapeutic interventions alongside standard antidepressant management.
  • Depressive episodes occur at a specific time of year, most commonly autumn or winter, with full remissions occurring at predictable times, typically spring, demonstrated for at least 2 consecutive years without non-seasonal episodes during that period.
  • First-line approach: First-line interventions include bright light therapy using a 10,000 lux light box for 20 to 30 minutes every morning starting in early autumn, vitamin D supplementation at 2000 to 5000 IU daily, regular exercise, and SSRI pharmacotherapy.
  • Board trap. Confusing seasonal pattern specifier with temporary holiday stress or adjustment disorder. Seasonal pattern requires recurrent full winter depressive episodes with spring remissions over consecutive years.

  Board trap. Board trap. Confusing seasonal pattern specifier with temporary holiday stress or adjustment disorder. Seasonal pattern requires recurrent full winter depressive episodes with spring remissions over consecutive years.

• Anxious Distress SpecifierWhat it is: Depressive episode accompanied by prominent anxiety symptoms, including feeling keyed up or tense, unusual restlessness, difficulty concentrating due to worry, fear that something awful might happen, or fear of losing control.

  • What it is: Depressive episode accompanied by prominent anxiety symptoms, including feeling keyed up or tense, unusual restlessness, difficulty concentrating due to worry, fear that something awful might happen, or fear of losing control.
  • Why boards care: Co-occurring anxious distress increases suicide risk, duration of illness, and treatment resistance.
  • First-line approach: First-line choices are SSRIs or SNRIs.
  • Board trap. Prescribing bupropion as a first-line agent when severe anxious distress or panic is prominent. Bupropion can exacerbate severe anxiety, agitation, and restlessness.
  • Safety alert. Patients with major depressive disorder and anxious distress have higher rates of treatment failure and active suicidal ideation, requiring close safety monitoring during early treatment phases.

  Board trap. Board trap. Prescribing bupropion as a first-line agent when severe anxious distress or panic is prominent. Bupropion can exacerbate severe anxiety, agitation, and restlessness.

  Safety. Safety alert. Patients with major depressive disorder and anxious distress have higher rates of treatment failure and active suicidal ideation, requiring close safety monitoring during early treatment phases.

• Which of the following is not a DSM-5-TR criterion for a major depressive episode?B. Loss of food enjoyment

  • B. Loss of food enjoyment
  • D. Altered mood associated with bereavement
• Differential: Bereavement vs MDDMajor depressive disorder requires at least 5 of 9 SIGECAPS symptoms present for at least 2 weeks, with at least 1 symptom being depressed mood or loss of interest or pleasure.

  • Major depressive disorder requires at least 5 of 9 SIGECAPS symptoms present for at least 2 weeks, with at least 1 symptom being depressed mood or loss of interest or pleasure.
  • Bereavement involves feelings of emptiness and loss that occur in waves or pangs of grief associated with thoughts or memories of the deceased, rather than persistent depressed mood.
  • Self-esteem is generally preserved in normal bereavement, whereas pervasive worthlessness, self-loathing, and inappropriate guilt occur in major depressive disorder.
  • Suicidal ideation in bereavement centers on joining the deceased, whereas in major depressive disorder, it stems from feeling worthless, unable to cope, or being a burden.
  • In DSM-5-TR, bereavement does not exclude a diagnosis of major depressive disorder if full criteria of 5 of 9 symptoms for 2 weeks are met following a major loss.
  • First-line management for uncomplicated bereavement is supportive counseling and psychoeducation, whereas major depressive disorder requires evidence-based psychotherapy such as CBT or IPT and/or pharmacotherapy with SSRIs like sertraline or escitalopram.
• Bereavement vs. Major Depressive DisorderThink: Bereavement features waves of grief linked to memories with preserved self-esteem, whereas major depressive disorder features persistent, unremitting depressed mood and pervasive worthlessness.

  • Think: Bereavement features waves of grief linked to memories with preserved self-esteem, whereas major depressive disorder features persistent, unremitting depressed mood and pervasive worthlessness.
  • Priority: Differentiate normal grief reactions from clinical depression to prevent unnecessary medication use or missing active suicide risk.
  • Boards are testing: Recognizing that bereavement is not a core DSM-5-TR criterion for major depressive disorder, and identifying when grief crosses into a clinical depressive episode.
• Clinical Characteristics ContrastMood pattern in bereavement: Depressed mood occurs in waves or pangs of grief triggered by reminders, interspersed with temporary periods of positive emotions and humor.

  • Mood pattern in bereavement: Depressed mood occurs in waves or pangs of grief triggered by reminders, interspersed with temporary periods of positive emotions and humor.
  • Mood pattern in major depressive disorder: Depressed mood is persistent, pervasive, and unremitting across a minimum 2-week timeline.
  • Thought content in bereavement: Preoccupation with thoughts and memories of the deceased.
  • Thought content in major depressive disorder: Self-critical, self-reproachful, pessimistic, and ruminative self-blame.
  • Self-esteem in bereavement: Preserved; self-derogation, if present, typically relates to perceived failures toward the deceased.
  • Self-esteem in major depressive disorder: Marked feelings of worthlessness, self-loathing, and excessive or delusional guilt.

  Safety. Suicidal thoughts in bereavement focus on joining the deceased. Suicidal thoughts in major depressive disorder focus on ending life due to worthlessness, despair, or feeling like a burden.

• Signposts and Board PearlsSupportive counseling, active listening, and monitoring are first-line for uncomplicated bereavement. SSRIs like sertraline or escitalopram and structured therapies like CBT or IPT are first-line for major depressive disorder.

  • Supportive counseling, active listening, and monitoring are first-line for uncomplicated bereavement. SSRIs like sertraline or escitalopram and structured therapies like CBT or IPT are first-line for major depressive disorder.
  • Selecting bereavement as an automatic exclusion for diagnosing major depressive disorder. The DSM-5-TR removed the bereavement exclusion; clinicians must diagnose major depressive disorder if 5 of 9 SIGECAPS criteria for 2 weeks are present after a loss.
  • Never assume passive suicidal ideation after a major loss is benign grief. Perform an immediate assessment of ideation, intent, plan, and access to lethal means.

  Board trap. Selecting bereavement as an automatic exclusion for diagnosing major depressive disorder. The DSM-5-TR removed the bereavement exclusion; clinicians must diagnose major depressive disorder if 5 of 9 SIGECAPS criteria for 2 weeks are present after a loss.

  Safety. Never assume passive suicidal ideation after a major loss is benign grief. Perform an immediate assessment of ideation, intent, plan, and access to lethal means.

• Active Recall Checkpoints1. What is the minimum timeline required for symptoms to meet criteria for a major depressive episode?

  • 1. What is the minimum timeline required for symptoms to meet criteria for a major depressive episode?
  • 2. How do feelings of self-esteem differ between normal bereavement and major depressive disorder?
  • 3. What is the core difference in suicidal ideation content between bereavement and major depressive disorder?
  • 4. What 2 cardinal symptoms require at least 1 to be present to diagnose major depressive disorder under SIGECAPS?
  • 5. Did the DSM-5-TR keep or remove the bereavement exclusion for diagnosing major depressive disorder?
• Sample Question 16: Manifestation of DepressionDiagnosis of major depressive disorder requires 5 or more symptoms present nearly every day for at least a 2-week period, with at least 1 core symptom being depressed mood or anhedonia.

  • Diagnosis of major depressive disorder requires 5 or more symptoms present nearly every day for at least a 2-week period, with at least 1 core symptom being depressed mood or anhedonia.
  • Lifetime prevalence of major depressive disorder is 12 percent, affecting females twice as often as males, with a mean age of onset between 20 and 35 years.
  • Following symptom remission, antidepressant pharmacotherapy must be continued for 4 to 9 months during the continuation phase to prevent early relapse.
  • Discontinuation of antidepressants requires a gradual taper over approximately 6 weeks to avoid antidepressant discontinuation syndrome.
  • Maintenance phase therapy is indicated for patients with 3 or more lifetime episodes of major depressive disorder or significant ongoing risk factors.
  • Psychotherapy alone is evidence-based for mild to moderate major depressive disorder, whereas severe depression requires pharmacotherapy or combination treatment.
• Differential Diagnoses and SpecifiersPersistent depressive disorder: Chronic depressed mood present for at least 2 years in adults or 1 year in children, without a symptom-free interval exceeding 2 months.

  • Persistent depressive disorder: Chronic depressed mood present for at least 2 years in adults or 1 year in children, without a symptom-free interval exceeding 2 months.
  • Adjustment disorder with depressed mood: Emotional or behavioral symptoms occurring within 3 months of an identifiable stressor that do not meet full criteria for major depressive disorder.
  • Premenstrual dysphoric disorder: Cyclic mood lability, irritability, or anxiety occurring during the luteal phase before menses and remitting shortly after onset of menses.
• High-Yield Exam SignpostsFirst-line initial treatment for mild to moderate major depressive disorder includes SSRIs, SNRIs, or evidence-based psychotherapy such as cognitive behavioral therapy or interpersonal psychotherapy.

  • First-line initial treatment for mild to moderate major depressive disorder includes SSRIs, SNRIs, or evidence-based psychotherapy such as cognitive behavioral therapy or interpersonal psychotherapy.
  • Safety alert: Never discontinue psychotropic medications abruptly or immediately prior to major stressful life events, as abrupt withdrawal triggers severe discontinuation symptoms and heightened relapse risk.
  • Board trap: Assuming psychotherapy carries a higher relapse rate than medication when discontinuing care. In reality, psychotherapy teaches lasting cognitive and behavioral skill sets that provide lower long-term relapse rates than pharmacotherapy alone.

  Board trap. Board trap: Assuming psychotherapy carries a higher relapse rate than medication when discontinuing care. In reality, psychotherapy teaches lasting cognitive and behavioral skill sets that provide lower long-term relapse rates than pharmacotherapy alone.

  Safety. Safety alert: Never discontinue psychotropic medications abruptly or immediately prior to major stressful life events, as abrupt withdrawal triggers severe discontinuation symptoms and heightened relapse risk.

• Sample Question 18: Gender PrevalenceLifetime prevalence: Major depressive disorder has a lifetime prevalence of 12% in the general population.

  • Lifetime prevalence: Major depressive disorder has a lifetime prevalence of 12% in the general population.
  • Gender ratio: Women have twice the risk of major depressive disorder compared to men, establishing a 2 to 1 female-to-male prevalence ratio.
  • Age distribution: The mean age of onset for major depressive disorder is 20 to 35 years. Prevalence in young adults aged 18 to 29 years is 3 times higher than in adults over 60 years of age.
  • Genetic risk: Heritability is approximately 40%. First-degree biological relatives of individuals with major depressive disorder face a 2 to 4 times higher risk than the general population.
  • Socioeconomic risk: Lower education level and lower socioeconomic status are recognized demographic risk factors.
  • Medical inpatient risk: Hospitalized medical inpatients experience a 15% higher risk of major depressive disorder than the general population.
• High-Yield Clinical TeachingMajor depressive disorder is a cyclic, recurring condition characterized by a cluster of signs and symptoms where pathologic depressed mood or anhedonia causes significant social, occupational, or interpersonal disruption.

  • Major depressive disorder is a cyclic, recurring condition characterized by a cluster of signs and symptoms where pathologic depressed mood or anhedonia causes significant social, occupational, or interpersonal disruption.
• Demographics and Risk ArchitectureGender: Female gender is a major risk factor. Women are diagnosed at twice the rate of men.

  • Gender: Female gender is a major risk factor. Women are diagnosed at twice the rate of men.
  • Age: Depression is predominantly a disease of younger populations. Prevalence declines as age increases beyond age 60.
  • Race: Epidemiological data in Fitzgerald indicates a higher reported prevalence for whites than blacks.
  • Medical Setting: Physical illness increases vulnerability. Medical inpatients demonstrate a 15% higher risk of depression compared to community baselines.
  • Comorbidities: High rates of comorbidity exist with learning disabilities, ADHD, anxiety disorders, PTSD, conduct disorder, and substance use disorders.
• Key Signposts for Board MasteryFor mild to moderate major depressive disorder, first-line evidence-based options include psychotherapy alone (such as cognitive behavioral therapy or interpersonal psychotherapy), pharmacotherapy alone (such as an SSRI), or combination therapy.

  • Assuming older adults have the highest overall prevalence of major depressive disorder. Board test-writers frequently exploit this misconception. While depression in older adults carries unique risks, the highest overall prevalence occurs in young adults aged 18 to 29 years.
  • For mild to moderate major depressive disorder, first-line evidence-based options include psychotherapy alone (such as cognitive behavioral therapy or interpersonal psychotherapy), pharmacotherapy alone (such as an SSRI), or combination therapy.

  Board trap. Assuming older adults have the highest overall prevalence of major depressive disorder. Board test-writers frequently exploit this misconception. While depression in older adults carries unique risks, the highest overall prevalence occurs in young adults aged 18 to 29 years.

  Safety. Always screen for past manic or hypomanic episodes before diagnosing unipolar depression or prescribing psychotropics. Up to 10% of patients presenting with unipolar depression eventually experience a manic episode 6 to 10 years later. Prescribing an antidepressant as monotherapy

• A) More likely to occur in men than womenA: This choice is false in clinical reality, which makes it the correct answer to the question stem. Females carry two times the lifetime risk of males.

  • A: This choice is false in clinical reality, which makes it the correct answer to the question stem. Females carry two times the lifetime risk of males.
  • B: This choice is incorrect because the statement is true. Epidemiological data presented in Fitzgerald indicates a higher reported prevalence of major depressive disorder for whites than blacks.
  • C: This choice is incorrect because the statement is true. The population lifetime prevalence for major depressive disorder is 12%.
  • D: This choice is incorrect because the statement is true. Established risk factors include genetic predisposition (40% heritability, 2 to 4 times higher risk in first-degree relatives) and lower educational attainment.
• Key ClueA: Incorrect. Six months of symptom remission marks the continuation phase, but multiple underlying risk factors still predict high long-term recurrence rates (50% to 85% lifetime recurrence).

  • A: Incorrect. Six months of symptom remission marks the continuation phase, but multiple underlying risk factors still predict high long-term recurrence rates (50% to 85% lifetime recurrence).
  • B: Correct. Young age, recurrent episodes, chronic medical illness, and co-occurring anxiety interact to raise the risk of relapse.
  • C: Incorrect. Medical comorbidities increase depressive recurrence risk regardless of baseline glycemic control.
  • D: Incorrect. Sertraline does not cause pharmacological tolerance; the risk is driven by disease biology and demographic factors.
• Manic Episode CriteriaBipolar I disorder requires at least 1 manic episode lasting 1 week (7 consecutive days) or any duration if hospitalization is required.

  • Bipolar I disorder requires at least 1 manic episode lasting 1 week (7 consecutive days) or any duration if hospitalization is required.
  • Bipolar II disorder requires at least 1 major depressive episode (lasting 2 weeks) and at least 1 hypomanic episode (lasting 4 consecutive days), with no history of mania.
  • DIG FAST diagnostic criteria require at least 3 symptoms (or 4 symptoms if mood is only irritable) out of 7: Distractibility, Indiscretion/Impulsivity, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, and Talkativeness.
  • Mania vs. Hypomania: Mania causes marked occupational or social impairment, may require hospitalization, or includes psychotic features. Hypomania causes a distinct, observable change in functioning for at least 4 days without marked impairment, hospitalization, or psychosis.
  • Antidepressant rule: Antidepressant-induced mania that persists at a full syndromal level beyond the physiological effect of the drug meets full criteria for bipolar I disorder.
  • Mixed features: Defined as meeting full manic or hypomanic criteria while simultaneously experiencing at least 3 depressive symptoms.
• The DIG FAST Symptom ClusterDistractibility: Attention is easily drawn to unimportant or irrelevant external stimuli .

  • Distractibility: Attention is easily drawn to unimportant or irrelevant external stimuli .
  • Indiscretion: Excessive involvement in activities with a high potential for painful consequences, such as buying sprees, financial recklessness, or sexual indiscretions .
  • Grandiosity: Inflated self-esteem or delusional grandiosity .
  • Flight of ideas: Subjective experience that thoughts are racing or rapid, disorganized speech .
  • Activity increase: Increased goal-directed activity at work, school, or socially, or psychomotor agitation .
  • Sleep deficit: Decreased need for sleep, such as feeling fully rested after only 2 to 3 hours of sleep .
• Board TrapBoard trap**: Test writers often present a patient who develops manic symptoms after starting an **antidepressant** or steroid .

  • Board trap**: Test writers often present a patient who develops manic symptoms after starting an **antidepressant** or steroid .
  • Do not automatically classify this as a simple drug side effect .
  • If the manic episode persists at a full syndromal level beyond the expected physiological effect of the medication, the correct diagnostic label is **bipolar I disorder** .
  • Another trap is assuming patients will spontaneously report past elevated mood .

  Board trap. Test writers often present a patient who develops manic symptoms after starting an antidepressant or steroid . Do not automatically classify this as a simple drug side effect . If the manic episode persists at a full syndromal level beyond the expected physiological effect of the

• First-Line InterventionsFirst-line monotherapy for acute euphoric mania consists of lithium or valproate, or a second-generation antipsychotic such as olanzapine, quetiapine, or risperidone . For severe acute agitation, a second-generation antipsychotic provides a faster onset of control than a traditio

  • First-line**: First-line monotherapy for acute euphoric mania consists of **lithium** or **valproate**, or a second-generation antipsychotic such as **olanzapine**, **quetiapine**, or **risperidone** .
  • For severe acute agitation, a second-generation antipsychotic provides a faster onset of control than a traditional mood stabilizer .
  • Short-term adjunctive **benzodiazepines** like **lorazepam** or **clonazepam** may be added for acute insomnia and psychomotor agitation .
  • Antidepressant monotherapy must be tapered and discontinued .
• Comparing Mania, Hypomania, and CyclothymiaMania: Requires at least 1 week of symptoms . Causes marked impairment in social or occupational functioning, may require hospitalization, or may feature psychotic features . Confirms a diagnosis of bipolar I disorder .

  • Mania: Requires at least 1 week of symptoms . Causes marked impairment in social or occupational functioning, may require hospitalization, or may feature psychotic features . Confirms a diagnosis of bipolar I disorder .
  • Cyclothymic Disorder: Requires at least 2 years in adults (1 year in children) of fluctuating hypomanic and depressive symptoms that occur for at least half the time and never meet full criteria for a major depressive, manic, or hypomanic episode .
• Hypomanic Episode CriteriaHypomanic episode criteria require an elevated, expansive, or irritable mood along with persistently increased energy or goal-directed activity lasting at least 4 consecutive days.

  • Hypomanic episode criteria require an elevated, expansive, or irritable mood along with persistently increased energy or goal-directed activity lasting at least 4 consecutive days.
  • Diagnosis requires 3 or more DIG FAST symptoms (4 symptoms if the mood is exclusively irritable), representing an unequivocal change in functioning that is observable by others.
  • A hypomanic episode causes no marked impairment in social or occupational functioning, requires no hospitalization, and features no psychotic symptoms.
  • If hospitalization is required or if psychotic features are present, the episode is automatically classified as a manic episode, establishing a diagnosis of Bipolar I disorder.
  • Bipolar II disorder requires at least 1 hypomanic episode and at least 1 major depressive episode. It is the most common bipolar subtype misdiagnosed as unipolar major depressive disorder.
  • Rapid cycling is defined as 4 or more mood episodes (depressive, manic, or hypomanic) within a 12-month period.
• Hypomanic Episode vs. Manic EpisodeThink: Hypomania is at least 4 days without marked impairment, hospitalization, or psychosis. Mania is at least 1 week (or any duration if hospitalized) with marked impairment, psychosis, or hospitalization.

  • Think: Hypomania is at least 4 days without marked impairment, hospitalization, or psychosis. Mania is at least 1 week (or any duration if hospitalized) with marked impairment, psychosis, or hospitalization.
  • Priority: Assess physical safety, risk of harm, and need for inpatient admission.
  • Boards are testing: Hospitalization or psychotic symptoms automatically equal mania, regardless of symptom duration.
• Bipolar I Disorder vs. Bipolar II DisorderThink: Bipolar I requires at least 1 manic episode (major depressive episodes are common but technically not required for diagnosis). Bipolar II requires at least 1 hypomanic episode AND at least 1 major depressive episode.

  • Think: Bipolar I requires at least 1 manic episode (major depressive episodes are common but technically not required for diagnosis). Bipolar II requires at least 1 hypomanic episode AND at least 1 major depressive episode.
  • Priority: Differentiate full mania from hypomania to select correct maintenance pharmacotherapy and assess safety.
  • Boards are testing: Bipolar II is the subtype most often misdiagnosed as unipolar depression because patients only seek help when depressed.
• Cyclothymic Disorder vs. Bipolar II DisorderThink: Cyclothymia is chronic mood instability lasting at least 2 years in adults (1 year in children) with hypomanic and depressive symptoms that never meet full criteria for a hypomanic or major depressive episode.

  • Think: Cyclothymia is chronic mood instability lasting at least 2 years in adults (1 year in children) with hypomanic and depressive symptoms that never meet full criteria for a hypomanic or major depressive episode.
  • Priority: Recognize long-standing subclinical mood instability that has not caused severe occupational disruption or legal trouble.
  • Boards are testing: Cyclothymia involves subclinical fluctuations for at least 2 years without ever meeting full MDD or hypomania thresholds.
• Psychopharmacology and Laboratory Safety PearlsIndication: Preferred for classic euphoric, grandiose mania and maintenance. Has independent anti-suicide evidence.

  • Indication: Preferred for classic euphoric, grandiose mania and maintenance. Has independent anti-suicide evidence.
  • Therapeutic Range: 0.8 to 1.2 mEq/L for acute mania; 0.6 to 1.0 mEq/L for maintenance.
  • Baseline Workup: BUN, serum creatinine, eGFR, TSH, serum electrolytes, CBC, ECG (if over age 50), and pregnancy test.
  • Toxicity Warning: Toxicity begins near 1.5 mEq/L with tremor, ataxia, confusion, nausea, and diarrhea. Dehydration, low sodium, NSAIDs, ACE inhibitors, and thiazide diuretics elevate lithium levels. Prednisone does not alter lithium levels.
  • Valproate (Depakote):
  • Indication: Preferred for dysphoric or irritable mania, mixed features, comorbid substance use, or traumatic brain injury.

  Safety. Black box warning for Stevens-Johnson syndrome rash. Must start at 25 mg daily for 2 weeks, then 50 mg daily for 2 weeks, then 100 mg, then 200 mg. No routine baseline lab monitoring is required.

• Mnemonic: DIG FASTBipolar I disorder requires at least 1 manic episode lasting at least 1 week or requiring hospitalization, characterized by abnormally elevated, expansive, or irritable mood and increased goal-directed energy.

  • Bipolar I disorder requires at least 1 manic episode lasting at least 1 week or requiring hospitalization, characterized by abnormally elevated, expansive, or irritable mood and increased goal-directed energy.
  • Bipolar II disorder requires at least 1 major depressive episode lasting 2 weeks and at least 1 hypomanic episode lasting 4 consecutive days, with no history of full mania.
  • The DIG FAST mnemonic identifies the 7 cardinal manic and hypomanic symptoms: Distractibility, Indiscretion, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, and Talkativeness.
  • Diagnostic criteria require at least 3 DIG FAST symptoms if mood is elevated or expansive, or at least 4 symptoms if mood is solely irritable.
  • Cyclothymic disorder involves chronic, fluctuating hypomanic and depressive symptoms for at least 2 years in adults (1 year in children) without meeting full criteria for a major depressive or manic episode.
  • Rapid cycling is defined by 4 or more distinct major mood episodes within a 12-month period.
• Diagnostic Criteria and DIG FAST BreakdownDistractibility: Attention is easily drawn to irrelevant outside stimuli.

  • Distractibility: Attention is easily drawn to irrelevant outside stimuli.
  • Indiscretion: Over-involvement in activities with high potential for painful consequences, such as reckless spending, foolish investments, or sexual indiscretions.
  • Grandiosity: Inflated self-esteem or delusional grandiosity, such as believing one possesses special powers or a divine mission.
  • Flight of ideas: Subjective feeling that thoughts are racing, or observed rapid shifting from topic to topic.
  • Activity increase: Increased goal-directed activity at work, school, or socially, or psychomotor agitation.
  • Sleep deficit: Decreased need for sleep, where the patient feels rested after only 2 to 3 hours.
• Comparing Mania vs HypomaniaManic episode: Mood must be abnormally elevated, expansive, or irritable for at least 1 week. Requires 3 DIG FAST symptoms, or 4 if mood is only irritable. Causes marked impairment in social or occupational functioning, requires hospitalization, or features psychotic symptoms.

  • Manic episode: Mood must be abnormally elevated, expansive, or irritable for at least 1 week. Requires 3 DIG FAST symptoms, or 4 if mood is only irritable. Causes marked impairment in social or occupational functioning, requires hospitalization, or features psychotic symptoms.
• Bipolar Spectrum SubtypesBipolar I disorder: Defined by at least 1 lifetime manic or mixed episode. Major depressive episodes occur in 90% of individuals but are not strictly required for formal diagnosis.

  • Bipolar I disorder: Defined by at least 1 lifetime manic or mixed episode. Major depressive episodes occur in 90% of individuals but are not strictly required for formal diagnosis.
  • Bipolar II disorder: Defined by at least 1 major depressive episode AND at least 1 hypomanic episode. Never includes a full manic episode.
  • Rapid cycling specifier: Characterized by 4 or more mood episodes (depressive, manic, or hypomanic) within a 12-month period.
  • With mixed features specifier: Full criteria met for mania or hypomania while simultaneously experiencing at least 3 concurrent depressive symptoms, or vice versa.
• Key SignpostsFor classic euphoric mania, lithium is first-line and reduces suicide risk. For acute agitation or aggressive mania, second-generation antipsychotics like olanzapine, quetiapine, or risperidone act faster than mood stabilizers. For dysphoric or irritable mania, mixed features, or

  • Antidepressant monotherapy with SSRIs or SNRIs in patients with bipolar disorder can precipitate acute mania, hypomania, or rapid cycling. Always taper and discontinue antidepressants during manic phases.

  Board trap. Misdiagnosing Bipolar II disorder as unipolar major depressive disorder. Patients rarely complain about hypomania because increased energy feels beneficial. Always obtain collateral history and screen for past periods of reduced sleep and hyperactivity before prescribing antidepr

  Safety. Antidepressant monotherapy with SSRIs or SNRIs in patients with bipolar disorder can precipitate acute mania, hypomania, or rapid cycling. Always taper and discontinue antidepressants during manic phases.

• Keyed letter: CA. Bipolar I disorder requires at least 1 full manic episode, which typically causes marked social or occupational impairment or requires emergency hospitalization.

  • A. Bipolar I disorder requires at least 1 full manic episode, which typically causes marked social or occupational impairment or requires emergency hospitalization.
  • B. Bipolar II disorder requires at least 1 full major depressive episode and at least 1 distinct hypomanic episode.
  • D. Dysthymia (persistent depressive disorder) involves chronic low-grade depression without hypomanic or manic mood swings.
• Keyed letter: BA. Dysthymia is a primary unipolar depressive condition without any history of hypomania or mania.

  • A. Dysthymia is a primary unipolar depressive condition without any history of hypomania or mania.
  • C. Bipolar I disorder involves overt manic episodes with severe dysfunction or psychosis that are readily recognized and unlikely to be mistaken for unipolar depression.
  • D. Cyclothymia consists of chronic low-level mood swings that do not meet full criteria for major depressive episodes.
• Table 8-1: Bipolar Genetics and RelapseBipolar I Lifetime Prevalence: Affects 1.5% of the population with an equal gender ratio between men and women, whereas Bipolar II affects 1.2% with a higher prevalence in women, bringing the overall bipolar spectrum prevalence up to 6%.

  • Bipolar I Lifetime Prevalence: Affects 1.5% of the population with an equal gender ratio between men and women, whereas Bipolar II affects 1.2% with a higher prevalence in women, bringing the overall bipolar spectrum prevalence up to 6%.
  • Age of Onset: The mean age of onset for bipolar disorder is 21 to 24 years, with an incidence in children and adolescents of 1%.
  • Genetic Risk & Twin Concordance: First-degree relatives of individuals with bipolar disorder carry a 5% to 10% risk, while monozygotic twin concordance reaches 40% to 50%.
  • Relapse Dynamics: Following a single manic episode, 90% of individuals experience recurrent mood episodes, and 40% to 50% of Bipolar I patients suffer a second manic episode within 2 years.
  • Depression Sequence: Up to 60% of manic episodes occur immediately before a major depressive episode, and 5% to 10% of patients initially diagnosed with major depressive disorder experience a manic episode 6 to 10 years after their first depression.
  • Environmental Triggers: Cannabis use and substance use disorders directly trigger the onset of a first manic episode and drive clinical relapses.
• Epidemiologic Prevalence and Gender PatternsMajor depressive disorder affects 12% of the population with a two-to-one female-to-male ratio, and its prevalence in young adults aged 18 to 29 is three times higher than in adults over age 60.

  • Major depressive disorder affects 12% of the population with a two-to-one female-to-male ratio, and its prevalence in young adults aged 18 to 29 is three times higher than in adults over age 60.
  • In contrast, the bipolar spectrum reaches up to 6% total prevalence. Within this spectrum, Bipolar I carries a 1.5% lifetime prevalence with equal rates in men and women, whereas Bipolar II carries a 1.2% lifetime prevalence and affects women more frequently than men.
  • Both conditions represent illnesses of younger populations, with major depression presenting at a mean age of 20 to 35 years and bipolar disorder presenting slightly earlier at a mean age of 21 to 24 years.
• Genetic Heritability and RiskFirst-degree relatives of individuals with major depressive disorder have a 2 to 4 times higher risk of depression than the general population, reflecting a 40% heritability rate.

  • First-degree relatives of individuals with major depressive disorder have a 2 to 4 times higher risk of depression than the general population, reflecting a 40% heritability rate.
  • First-degree relatives of individuals with bipolar disorder face a 5% to 10% lifetime risk.
  • Genetic concordance rises dramatically in monozygotic twins, who share a 40% to 50% risk for bipolar disorder, demonstrating a powerful genetic substrate.
• Etiology and Environmental Relapse DriversBipolar disorder etiology follows a lock and key model where genetic and biochemical vulnerability represents the lock, and acute external environmental stressors or life pressures act as the key that unlocks a manic episode.

  • Bipolar disorder etiology follows a lock and key model where genetic and biochemical vulnerability represents the lock, and acute external environmental stressors or life pressures act as the key that unlocks a manic episode.
  • Cannabis and substance use disorders are the primary environmental drivers that trigger initial manic conversion and cause subsequent mood relapses.
  • Medical inpatients face a 15% elevated risk for major depression compared to the general population, and non-mood comorbidities such as ADHD, anxiety, PTSD, and substance use frequently co-occur across both depressive and bipolar spectrums.
• Natural History, Recurrence, and ProgressionBipolar disorder is a chronic, recurring illness. A single manic episode carries a 90% lifetime probability of future recurrent mood episodes.

  • Bipolar disorder is a chronic, recurring illness. A single manic episode carries a 90% lifetime probability of future recurrent mood episodes.
  • Recurrence happens rapidly, with 40% to 50% of Bipolar I patients experiencing a second manic episode within 2 years of their first.
  • Manic episodes frequently transition directly into depression, with 60% of manic episodes occurring immediately prior to a major depressive episode.
  • Diagnostic conversion is common over time. Between 5% and 10% of patients presenting with unipolar major depressive disorder experience their first manic episode 6 to 10 years after their initial depressive presentation.
  • Multiple unipolar or bipolar mood episodes lead to neuroprogressive structural brain changes, cognitive impairment, and decreased treatment responsiveness during subsequent acute episodes.
• Signposted Board Pearls and TrapsLithium is first-line pharmacotherapy for classic euphoric mania and long-term maintenance, and valproate is first-line for dysphoric mania, mixed features, or comorbid substance use disorder.

  • Lithium is first-line pharmacotherapy for classic euphoric mania and long-term maintenance, and valproate is first-line for dysphoric mania, mixed features, or comorbid substance use disorder.
  • Antidepressant monotherapy in bipolar disorder is strictly contraindicated because it can precipitate manic conversion, rapid cycling, or mixed states.
  • Mistaking a first manic episode induced by an antidepressant as simple unipolar drug toxicity. If full manic criteria persist beyond the expected physiological effect of the antidepressant, the patient meets criteria for a primary Bipolar I diagnosis.
  • Integrate structured individual or group psychoeducation focused on regular sleep-wake rhythms and early relapse sign identification, which independently reduces relapse rates by 25% to 30%.
  • Lithium and clozapine are the only two psychotropic medications with proven independent anti-suicide efficacy.

  Board trap. Mistaking a first manic episode induced by an antidepressant as simple unipolar drug toxicity. If full manic criteria persist beyond the expected physiological effect of the antidepressant, the patient meets criteria for a primary Bipolar I diagnosis.

  Safety. Antidepressant monotherapy in bipolar disorder is strictly contraindicated because it can precipitate manic conversion, rapid cycling, or mixed states.

• Specifiers: Mixed and Rapid CyclingRapid cycling criteria: Defined as 4 or more distinct major mood episodes (major depressive, manic, or hypomanic) occurring within a 12-month period.

  • Rapid cycling criteria: Defined as 4 or more distinct major mood episodes (major depressive, manic, or hypomanic) occurring within a 12-month period.
  • Mixed features criteria: Requires meeting full criteria for a manic, hypomanic, or major depressive episode accompanied by at least 3 symptoms of the opposing pole during the majority of days.
  • First-line pharmacotherapy: Divalproex (valproate) or second-generation antipsychotics (such as quetiapine, olanzapine, or lurasidone) are first-line for mixed features and rapid cycling.
  • Lithium vs valproate selection: Lithium is first-line for classic euphoric mania, whereas valproate is first-line for dysphoric mania, mixed features, rapid cycling, traumatic brain injury, and comorbid substance use disorders.
  • Antidepressant contraindication: Antidepressant monotherapy is strictly contraindicated in bipolar disorder with mixed features or rapid cycling because it accelerates cycle frequency, worsens agitation, and increases suicide risk.
• Rapid Cycling SpecifierValproate or carbamazepine is the preferred mood stabilizer for rapid cycling. Second-generation antipsychotics like quetiapine or olanzapine also demonstrate strong efficacy.

  • Valproate or carbamazepine is the preferred mood stabilizer for rapid cycling. Second-generation antipsychotics like quetiapine or olanzapine also demonstrate strong efficacy.
  • Do not confuse rapid cycling with ultradian mood swings or borderline personality disorder mood lability. Rapid cycling requires distinct episodes meeting duration thresholds over a 12-month timeline, not hourly or daily emotional shifts.

  Board trap. Do not confuse rapid cycling with ultradian mood swings or borderline personality disorder mood lability. Rapid cycling requires distinct episodes meeting duration thresholds over a 12-month timeline, not hourly or daily emotional shifts.

  Safety. Antidepressant monotherapy must never be used in rapid cycling. Antidepressants frequently act as the driving catalyst behind rapid mood switching and can lock a patient into a continuous cycling pattern. When evaluating a patient with rapid cycling who is currently taking an ant

• Mixed Features SpecifierValproate or second-generation antipsychotics (quetiapine, olanzapine, lurasidone, ziprasidone) are first-line choices for mixed states.

  • Valproate or second-generation antipsychotics (quetiapine, olanzapine, lurasidone, ziprasidone) are first-line choices for mixed states.

  Board trap. Expect test writers to present a patient with severe depression who also exhibits racing thoughts, irritability, and decreased need for sleep. If you mistakenly diagnose unipolar depression and prescribe an SSRI alone, you will trigger severe agitation or mania. Always identify t

  Safety. Patients presenting with mixed features carry the highest immediate suicide risk across the bipolar spectrum. The combination of depressive despair and hopeless ideation paired with manic energy, impulsivity, and psychomotor agitation creates an acute emergency. Immediate safety

• Sample Question 125: DifferentiationBipolar I disorder requires at least 1 manic or mixed episode, whereas Bipolar II disorder requires at least 1 major depressive episode and at least 1 hypomanic episode with zero history of mania.

  • Bipolar I disorder requires at least 1 manic or mixed episode, whereas Bipolar II disorder requires at least 1 major depressive episode and at least 1 hypomanic episode with zero history of mania.
  • Diagnostic criteria for a manic episode require abnormally elevated, expansive, or irritable mood and increased goal-directed activity lasting at least 1 week, or any duration if hospitalization is required, with 3 or more DIG FAST symptoms (4 if mood is only irritable).
  • Hypomania requires the same DIG FAST symptom cluster lasting at least 4 consecutive days, causing an unequivocal change in functioning noticed by others, but never causing marked social or occupational impairment, never requiring hospitalization, and never featuring psychosis.
  • Rapid cycling specifier is defined as 4 or more major mood episodes (major depressive, manic, or hypomanic) within a 12-month period, whereas mixed features involves meeting full criteria for mania or hypomania with at least 3 co-occurring depressive symptoms (or vice versa).
  • First-line acute mania agents include lithium, valproate, carbamazepine, or second-generation antipsychotics; lithium is preferred for classic euphoric mania, while valproate is preferred for dysphoric mania, mixed features, or comorbid substance use.
  • Acute bipolar depression is treated with quetiapine 300 mg daily, lurasidone, lumateperone, lamotrigine, lithium, or olanzapine with fluoxetine; antidepressant monotherapy is strictly avoided due to the risk of triggering mania or rapid cycling.
• Mania versus HypomaniaMood and activity: Both conditions require abnormally elevated, expansive, or irritable mood accompanied by persistently increased goal-directed activity or energy.

  • Mood and activity: Both conditions require abnormally elevated, expansive, or irritable mood accompanied by persistently increased goal-directed activity or energy.
  • Timeline: Mania requires a duration of at least 1 week, unless hospitalization occurs sooner. Hypomania requires a duration of at least 4 consecutive days.
  • If a patient with elevated mood presents with psychotic features or requires psychiatric hospitalization for safety, the episode is automatically classified as mania, confirming a diagnosis of bipolar I disorder regardless of symptom duration.

  Safety. If a patient with elevated mood presents with psychotic features or requires psychiatric hospitalization for safety, the episode is automatically classified as mania, confirming a diagnosis of bipolar I disorder regardless of symptom duration.

• Bipolar I, Bipolar II, and CyclothymiaBipolar I disorder: Defined by the occurrence of at least 1 manic or mixed episode. Major depressive episodes occur in 90 percent of patients, but 10 percent experience manic episodes exclusively.

  • Bipolar I disorder: Defined by the occurrence of at least 1 manic or mixed episode. Major depressive episodes occur in 90 percent of patients, but 10 percent experience manic episodes exclusively.
  • Bipolar II disorder: Defined by at least 1 major depressive episode and at least 1 hypomanic episode, with no history of a full manic episode.
  • Patients with bipolar II disorder are frequently misdiagnosed with unipolar major depressive disorder because they seek treatment during distressing depressive phases and rarely report hypomanic periods, which feel pleasant, ego-syntonic, or highly productive.

  Board trap. Patients with bipolar II disorder are frequently misdiagnosed with unipolar major depressive disorder because they seek treatment during distressing depressive phases and rarely report hypomanic periods, which feel pleasant, ego-syntonic, or highly productive.

• Course Specifiers: Rapid Cycling and Mixed FeaturesRapid cycling specifier: Applied when an individual experiences 4 or more distinct major mood episodes (major depressive, manic, or hypomanic) within a single 12-month period.

  • Rapid cycling specifier: Applied when an individual experiences 4 or more distinct major mood episodes (major depressive, manic, or hypomanic) within a single 12-month period.
  • Mixed features specifier: Applied when full diagnostic criteria for a manic or hypomanic episode are met along with at least 3 co-occurring depressive symptoms, or when a major depressive episode presents with at least 3 manic or hypomanic symptoms.
• Psychopharmacology and Safety ParametersFirst-line acute mania management: Divalproex, lithium, carbamazepine, or second-generation antipsychotics. Second-generation antipsychotics demonstrate a faster onset of action for acute agitation and aggression compared to traditional mood stabilizers.

  • First-line acute mania management: Divalproex, lithium, carbamazepine, or second-generation antipsychotics. Second-generation antipsychotics demonstrate a faster onset of action for acute agitation and aggression compared to traditional mood stabilizers.
  • First-line acute bipolar depression: Quetiapine, lurasidone, lumateperone, lamotrigine, or lithium.
  • Antidepressant monotherapy is contraindicated in bipolar disorder because un-booted antidepressant use can precipitate acute mania or accelerate rapid cycling. Antidepressants should be tapered and discontinued if manic symptoms emerge.
  • Co-administering NSAIDs such as ibuprofen, ACE inhibitors such as lisinopril, or thiazide diuretics with lithium decreases renal clearance and precipitates severe lithium toxicity.
  • Carbamazepine genetic safety: Requires mandatory screening for the HLA-B*1502 allele in patients of Asian ancestry prior to initiation due to high risk of Stevens-Johnson syndrome.
  • Lamotrigine clinical pearl: Lamotrigine does not require baseline laboratory monitoring, but requires slow dosage escalation starting at 25 mg daily to prevent life-threatening rashes.

  Board trap. Co-administering NSAIDs such as ibuprofen, ACE inhibitors such as lisinopril, or thiazide diuretics with lithium decreases renal clearance and precipitates severe lithium toxicity.

  Safety. Antidepressant monotherapy is contraindicated in bipolar disorder because un-booted antidepressant use can precipitate acute mania or accelerate rapid cycling. Antidepressants should be tapered and discontinued if manic symptoms emerge.

• Keyed letter: DA: Ibuprofen is an NSAID that reduces renal blood flow and lithium clearance, significantly elevating serum lithium levels.

  • A: Ibuprofen is an NSAID that reduces renal blood flow and lithium clearance, significantly elevating serum lithium levels.
  • B: Lisinopril is an ACE inhibitor that reduces lithium excretion through renal hemodynamic changes, creating a high risk of lithium toxicity.
  • C: A drop in GFR below 60 mL/min reflects impaired renal clearance, causing lithium accumulation and toxicity.
• Sample Question 126: Bipolar II DefinitionBipolar II disorder requires at least one major depressive episode lasting at least 2 weeks and at least one hypomanic episode lasting at least 4 consecutive days.

  • Bipolar II disorder requires at least one major depressive episode lasting at least 2 weeks and at least one hypomanic episode lasting at least 4 consecutive days.
  • A lifetime history of even one full manic episode permanently excludes the diagnosis of bipolar II disorder and establishes bipolar I disorder.
  • Bipolar II disorder has a lifetime prevalence of 1.2% in the general population and is more prevalent in females than males, with a mean age of onset between 21 and 24 years.
  • First-line pharmacotherapy for acute bipolar depression includes quetiapine, lurasidone, lumateperone, lamotrigine, or lithium.
  • Antidepressant monotherapy is contraindicated in bipolar II disorder due to the high risk of inducing mood switching into hypomania or mania, as well as rapid cycling.
• Diagnostic Criteria and TimelinesMajor depressive episode requirement: Must meet full DSM-5-TR criteria for at least 2 weeks, including at least 5 of 9 SIGECAPS symptoms with depressed mood or anhedonia.

  • Major depressive episode requirement: Must meet full DSM-5-TR criteria for at least 2 weeks, including at least 5 of 9 SIGECAPS symptoms with depressed mood or anhedonia.
  • Hypomanic episode requirement: Must persist for at least 4 consecutive days with elevated or irritable mood plus 3 or 4 DIGFAST symptoms.
  • Exclusion criterion: Zero lifetime history of full manic episodes.
• Clinical DifferentiatorsFunctioning: Hypomania causes an observable change in behavior, but does not cause marked social or occupational impairment.

  • Functioning: Hypomania causes an observable change in behavior, but does not cause marked social or occupational impairment.
  • Hospitalization: Need for psychiatric hospitalization automatically classifies the episode as mania, resulting in a diagnosis of bipolar I disorder.
  • Psychotic features: Presence of delusions or hallucinations automatically defines the episode as mania, making the diagnosis bipolar I disorder.
• Epidemiology and GeneticsPrevalence: Lifetime prevalence is 1.2% for bipolar II disorder and 1.5% for bipolar I disorder, with the overall bipolar spectrum reaching up to 6%.

  • Prevalence: Lifetime prevalence is 1.2% for bipolar II disorder and 1.5% for bipolar I disorder, with the overall bipolar spectrum reaching up to 6%.
  • Gender distribution: Bipolar II disorder affects females more frequently than males, whereas bipolar I disorder affects males and females equally.
  • Heritability: First-degree relatives of individuals with bipolar disorder have a 5% to 10% risk, which increases to 40% to 50% among monozygotic twins.
• Exam SignpostsEvidence-based treatments for bipolar depression in bipolar II disorder are quetiapine (target 300 mg daily at bedtime), lurasidone, lumateperone, lamotrigine (slowly titrated to prevent Stevens-Johnson syndrome), or lithium.

  • Evidence-based treatments for bipolar depression in bipolar II disorder are quetiapine (target 300 mg daily at bedtime), lurasidone, lumateperone, lamotrigine (slowly titrated to prevent Stevens-Johnson syndrome), or lithium.
  • Suicide risk in bipolar II disorder is extremely high during major depressive episodes and mixed states, requiring continuous safety and lethality assessments.
  • Prescribing SSRI monotherapy to a depressed patient without screening for past hypomania. Antidepressant monotherapy can trigger mood switching, rapid cycling (4 or more mood episodes in 12 months), or treatment resistance.

  Board trap. Prescribing SSRI monotherapy to a depressed patient without screening for past hypomania. Antidepressant monotherapy can trigger mood switching, rapid cycling (4 or more mood episodes in 12 months), or treatment resistance.

  Safety. Suicide risk in bipolar II disorder is extremely high during major depressive episodes and mixed states, requiring continuous safety and lethality assessments.

• Compare and DistinguishBipolar II Disorder vs. Bipolar I Disorder.

  • Bipolar II Disorder vs. Bipolar I Disorder.
  • Think: Bipolar II is hypomania plus major depression. Bipolar I is full mania (major depression is common but not required for diagnosis).
  • Priority: Evaluate for any history of psychiatric hospitalization, psychosis, or severe impairment in daily life.
  • Boards are testing: Remembering that a single episode of full mania defines bipolar I disorder forever, regardless of how many depressive or hypomanic episodes occur.
  • Bipolar II Disorder vs. Unipolar Major Depressive Disorder.
  • Think: Unipolar depression has no history of elevated mood or hypomania.
• Sample Question 127: DIGFAST ComponentsBipolar I disorder requires at least 1 manic episode lasting 7 consecutive days or requiring hospitalization, characterized by elevated, expansive, or irritable mood plus increased goal-directed activity.

  • Bipolar I disorder requires at least 1 manic episode lasting 7 consecutive days or requiring hospitalization, characterized by elevated, expansive, or irritable mood plus increased goal-directed activity.
  • Bipolar II disorder requires at least 1 major depressive episode lasting 2 weeks and at least 1 hypomanic episode lasting at least 4 consecutive days, with no lifetime history of mania.
  • The DIGFAST mnemonic defines manic and hypomanic symptoms: Distractibility, Indiscretion, Grandiosity, Flight of ideas, Activity increase, Sleep deficit, and Talkativeness.
  • Diagnosis of mania or hypomania requires mood elevation plus goal-directed energy, along with at least 3 DIGFAST symptoms, or 4 symptoms if the mood is only irritable.
  • Rapid cycling specifier requires 4 or more distinct mood episodes within a 12-month period.
  • First-line pharmacotherapy for acute euphoric mania is lithium or a second-generation antipsychotic, while valproate is preferred for dysphoric mania, mixed features, or comorbid substance use.

  Board trap. Patients with bipolar II disorder are frequently misdiagnosed with unipolar depression because they present for care during depressive episodes and do not report productive hypomanic periods.

  Safety. Antidepressants used as monotherapy in bipolar disorder can induce acute mania or accelerate rapid cycling and must be tapered and discontinued during manic episodes.

• DIGFAST Mnemonic and Diagnostic CriteriaDistractibility: Attention is easily drawn to irrelevant outside stimuli.

  • Distractibility: Attention is easily drawn to irrelevant outside stimuli.
  • Indiscretion: Excessive involvement in activities with high potential for painful consequences, such as buying sprees, sexual indiscretions, or foolish business investments.
  • Grandiosity: Inflated self-esteem or grandiose beliefs, ranging from exaggerated self-confidence to frank delusions of special status or divine mission.
  • Flight of ideas: Subjective experience that thoughts are racing or rapid continuous speech with abrupt topic switches.
  • Activity increase: Increased goal-directed activity at work, school, socially, or psychomotor agitation like pacing or restlessness.
  • Sleep deficit: Decreased need for sleep, such as feeling fully rested after only 2 or 3 hours of sleep.
• Concept: ManiaLithium, valproate, carbamazepine, or second-generation antipsychotics like quetiapine, olanzapine, or risperidone.

  • Timeline: Lasts at least 1 week, or any duration if hospitalization is required.
  • Symptom threshold: Elevated mood plus increased activity, plus 3 or more DIGFAST symptoms, or 4 if mood is irritable.
  • Impairment: Causes marked impairment in social or occupational functioning, or necessitates hospitalization to prevent harm, or exhibits psychotic features.
  • Lithium, valproate, carbamazepine, or second-generation antipsychotics like quetiapine, olanzapine, or risperidone.
• Concept: HypomaniaLithium, valproate, or second-generation antipsychotics. Never use antidepressant monotherapy.

  • Timeline: Lasts at least 4 consecutive days.
  • Symptom threshold: Same 3 or 4 DIGFAST symptoms as mania.
  • Impairment: Causes an unequivocal change in functioning observable by others, but is not severe enough to cause marked occupational impairment, does not require hospitalization, and never features psychosis.
  • Lithium, valproate, or second-generation antipsychotics. Never use antidepressant monotherapy.
• Mixed Features and Rapid CyclingMixed features: Criteria are met for a manic or hypomanic episode, and at least 3 depressive symptoms are present simultaneously during the majority of days. Alternatively, a major depressive episode presents with at least 3 manic or hypomanic symptoms.

  • Mixed features: Criteria are met for a manic or hypomanic episode, and at least 3 depressive symptoms are present simultaneously during the majority of days. Alternatively, a major depressive episode presents with at least 3 manic or hypomanic symptoms.
  • Rapid cycling: The occurrence of 4 or more mood episodes (major depressive, manic, or hypomanic) within a 12-month period.
  • Board trap. Prescribing antidepressant monotherapy in patients with mixed features or rapid cycling accelerates episode frequency and worsens mood instability. Valproate or lithium combined with an antipsychotic is the correct choice.

  Board trap. Prescribing antidepressant monotherapy in patients with mixed features or rapid cycling accelerates episode frequency and worsens mood instability. Valproate or lithium combined with an antipsychotic is the correct choice.

• Clinical Safety and Exam SignpostsClassical euphoric mania responds best to lithium. Dysphoric or irritable mania, mixed features, rapid cycling, or comorbid substance use responds best to valproate.

  • Safety alert. Unopposed antidepressant therapy in bipolar spectrum disorders can trigger manic conversion or rapid cycling. Antidepressants must be tapered and discontinued when manic symptoms emerge.
  • First-line. Classical euphoric mania responds best to lithium. Dysphoric or irritable mania, mixed features, rapid cycling, or comorbid substance use responds best to valproate.

  Safety. Unopposed antidepressant therapy in bipolar spectrum disorders can trigger manic conversion or rapid cycling. Antidepressants must be tapered and discontinued when manic symptoms emerge.

• Bipolar Depression TreatmentFirst-line monotherapy options for acute bipolar depression include quetiapine at 300 mg daily, lurasidone, lumateperone, lamotrigine, or lithium.

  • First-line monotherapy options for acute bipolar depression include quetiapine at 300 mg daily, lurasidone, lumateperone, lamotrigine, or lithium.
  • Antidepressant monotherapy is strictly contraindicated in bipolar depression due to the high risk of precipitating acute mania, hypomania, or rapid cycling.
  • When an antidepressant is required, it must be paired with a mood stabilizer or an atypical antipsychotic, such as the olanzapine-fluoxetine combination.
  • Lithium and clozapine are the only two psychiatric medications with proven, independent anti-suicide effects in patients with bipolar disorder.
  • Target therapeutic serum lithium levels are 0.8 to 1.2 mEq/L for acute episodes and 0.6 to 1.0 mEq/L for maintenance, measured as a 12-hour trough level after 4 days of consistent dosing.
  • Lamotrigine requires no baseline laboratory monitoring but demands a slow, 5-week dose titration starting at 25 mg daily for 2 weeks to prevent life-threatening Stevens-Johnson syndrome.
• First-Line Treatment Selection and Severity MatchingFirst-line monotherapy agents for acute bipolar depression include quetiapine at a target dose of 300 mg daily, lurasidone, lumateperone, lamotrigine, and lithium.

  • First-line monotherapy agents for acute bipolar depression include quetiapine at a target dose of 300 mg daily, lurasidone, lumateperone, lamotrigine, and lithium.
  • Combination therapy using the olanzapine-fluoxetine combination is also an evidence-based first-line choice when antidepressant coverage is necessary.
  • If a patient on an antidepressant develops manic or hypomanic symptoms, the provider must immediately taper and discontinue the antidepressant while maintaining or optimizing mood stabilizer therapy.

  Board trap. Never prescribe antidepressant monotherapy with an SSRI or SNRI for a patient with bipolar depression. Antidepressants used without a co-prescribed mood stabilizer or atypical antipsychotic can induce acute mania, hypomania, or rapid cycling. If full manic criteria emerge during

  Safety. If a patient on an antidepressant develops manic or hypomanic symptoms, the provider must immediately taper and discontinue the antidepressant while maintaining or optimizing mood stabilizer therapy.

• Lithium Pharmacotherapy, Safety Alerts, and ToxicityLithium remains a cornerstone of acute and maintenance therapy for bipolar disorder.

  • Lithium remains a cornerstone of acute and maintenance therapy for bipolar disorder.
  • First-line indication: Lithium is especially effective for classical euphoric or grandiose mania and for preventing recurrent depressive and manic episodes.
  • Suicide prevention: Lithium possesses a proven, independent anti-suicide effect in bipolar disorder, reducing completed suicide rates significantly.
  • Dosing and blood level monitoring: Draw a 12-hour post-dose serum trough level after 4 days on a stable dose. Acute therapeutic levels are 0.8 to 1.2 mEq/L, while maintenance levels are 0.6 to 1.0 mEq/L.
  • Baseline laboratory requirements: Before starting lithium, order serum creatinine, BUN, GFR, TSH, electrolytes, CBC with differential, serum hCG pregnancy test, urinalysis, and an EKG in patients over age 50.
  • Maintenance lab monitoring: Check creatinine, BUN, GFR, TSH, and a 12-hour trough level every 4 to 8 weeks initially, then every 6 to 12 months in stable patients.

  Board trap. Co-prescribing NSAIDs such as ibuprofen, ACE inhibitors such as lisinopril, or thiazide diuretics reduces renal excretion and precipitates lithium toxicity. Corticosteroids like prednisone do not alter renal lithium clearance or increase toxicity risk.

  Safety. Lithium is strictly contraindicated in acute renal failure, severe dehydration, and sodium depletion. In chronic kidney disease, if the GFR drops below 60 mL/min, the dose must be reduced and monitored closely.

• Lamotrigine Titration and Safety WarningsLamotrigine is an evidence-based first-line monotherapy for acute bipolar depression and long-term maintenance.

  • Lamotrigine is an evidence-based first-line monotherapy for acute bipolar depression and long-term maintenance.
  • Lab monitoring pearl: Lamotrigine does NOT require baseline or routine laboratory monitoring.
  • Standard titration schedule: Start at 25 mg daily for 2 weeks, increase to 50 mg daily for 2 weeks, then 100 mg daily for 1 week, reaching the standard target maintenance dose of 200 mg daily by week 5.
  • Rapid dose escalation or skipping steps during titration increases the risk of severe, life-threatening cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients must be educated to report any new skin rash immediately.

  Safety. Rapid dose escalation or skipping steps during titration increases the risk of severe, life-threatening cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients must be educated to report any new skin rash immediately.

• Second-Generation Antipsychotics and Combination RegimensQuetiapine at 300 mg daily monotherapy provides robust antidepressant efficacy in bipolar depression.

  • Quetiapine at 300 mg daily monotherapy provides robust antidepressant efficacy in bipolar depression.
  • Lurasidone and lumateperone offer effective monotherapy or adjunctive therapy for bipolar depression with a favorable metabolic profile.
  • Olanzapine-fluoxetine combination blends an atypical antipsychotic with an SSRI to safely treat acute bipolar depression while protecting against manic switching.
  • Olanzapine and quetiapine carry significant risks of metabolic syndrome, including severe weight gain, dyslipidemia, and new-onset diabetes mellitus. Baseline fasting glucose, lipid panel, weight, and BMI must be monitored periodically.

  Board trap. Olanzapine and quetiapine carry significant risks of metabolic syndrome, including severe weight gain, dyslipidemia, and new-onset diabetes mellitus. Baseline fasting glucose, lipid panel, weight, and BMI must be monitored periodically.

• Valproate, Carbamazepine, and Refractory StrategiesCarbamazepine requires baseline liver enzymes, CBC, and genetic screening for the HLA-B*1502 allele in patients of Asian descent prior to initiation due to high Stevens-Johnson syndrome risk.

  • Carbamazepine requires baseline liver enzymes, CBC, and genetic screening for the HLA-B*1502 allele in patients of Asian descent prior to initiation due to high Stevens-Johnson syndrome risk.
  • Electroconvulsive therapy is the gold-standard treatment for refractory bipolar depression, acute life-threatening suicidality, severe depression during pregnancy, or psychotic depression.
• FDA Black Box WarningAll antidepressant classes carry an FDA black box warning for an increased risk of suicidal ideation and suicidal behavior in children, adolescents, and young adults up to age 24.

  • All antidepressant classes carry an FDA black box warning for an increased risk of suicidal ideation and suicidal behavior in children, adolescents, and young adults up to age 24.
  • The warning specifically highlights an increased incidence of suicidal ideation and suicidal thoughts, not an increase in completed suicides.
  • In older adults aged 65 and older, antidepressant treatment is associated with a net reduction in suicide risk.
  • Mandatory clinical safety monitoring requires evaluating patients weekly or biweekly during the initial 4 to 8 weeks of therapy and following any dose modification.
  • Fluoxetine is FDA-approved for major depressive disorder in pediatric patients aged 8 and older, while escitalopram is approved for ages 12 and older.
  • Fluoxetine possesses a long elimination half-life of 84 hours for the parent drug and 7 to 15 days for its active metabolite, making it forgiving for missed doses, whereas paroxetine has a short half-life and carries the highest risk of discontinuation syndrome.
• Target Population and Age CutoffsThe warning specifically targets children, adolescents, and young adults up to **age 24** (under age 25).

  • The warning specifically targets children, adolescents, and young adults up to **age 24** (under age 25).
  • **Safety alert:** When initiating an **antidepressant** in any patient under **age 25**, you must establish a structured safety monitoring plan.
  • Plan for weekly or biweekly contact during the first 1 to 2 months of treatment to assess for emerging **suicidal ideation**, severe agitation, restlessness, panic, or unexpected shifts in behavior.
  • **Board trap:** Test writers frequently attempt to mislead candidates by stating that **antidepressants** increase completed suicides in young adults.

  Board trap. Test writers frequently attempt to mislead candidates by stating that antidepressants increase completed suicides in young adults. The exam tests the precise distinction that the FDA black box warning is for increased suicidal ideation and suicidal thoughts, not completed suicide

  Safety. When initiating an antidepressant in any patient under age 25, you must establish a structured safety monitoring plan. Plan for weekly or biweekly contact during the first 1 to 2 months of treatment to assess for emerging suicidal ideation, severe agitation, restlessness, panic,

• Pediatric Approvals and First-Line SelectionFluoxetine is the primary first-line antidepressant with FDA approval for major depressive disorder in pediatric patients down to age 8. Escitalopram holds FDA approval for major depressive disorder in adolescents aged 12 and older. In young adults, sertraline, fluoxetine, and es

  • First-line:** **Fluoxetine** is the primary first-line **antidepressant** with FDA approval for **major depressive disorder** in pediatric patients down to age 8.
  • **Escitalopram** holds FDA approval for **major depressive disorder** in adolescents aged 12 and older.
  • In young adults, **sertraline**, **fluoxetine**, and **escitalopram** are preferred first-line agents due to their overall safety and tolerability profiles.
• Pharmacokinetics, Half-Life, and DiscontinuationF: Flu-like symptoms (fatigue, lethargy, myalgias)

  • F: Flu-like symptoms (fatigue, lethargy, myalgias)
  • I: Insomnia and vivid dreams
  • N: Nausea and gastrointestinal distress
  • I: Imbalance (dizziness, vertigo, ataxia)
  • S: Sensory disturbances (paresthesias, electric shock sensations or brain zaps)
  • H: Hyperarousal (anxiety, agitation, frontal headache)
• Discontinuation SyndromeAntidepressant discontinuation syndrome occurs when SSRIs, SNRIs, or TCAs taken continuously for 6 weeks or longer are stopped abruptly or tapered too rapidly.

  • Antidepressant discontinuation syndrome occurs when SSRIs, SNRIs, or TCAs taken continuously for 6 weeks or longer are stopped abruptly or tapered too rapidly.
  • Paroxetine and venlafaxine carry the highest risk of discontinuation syndrome due to their short half-lives and lack of active metabolites.
  • Fluoxetine carries the lowest risk of discontinuation syndrome because its long parent half-life of 84 hours and active metabolite norfluoxetine half-life of 7 to 15 days create a built-in self-taper.
  • Symptoms typically emerge within 24 to 72 hours of stopping medication, last less than 7 days to 2 weeks, and are bothersome but not life-threatening.
  • Prevention requires a gradual dose taper over approximately 6 weeks. If severe withdrawal occurs, reinstate the original medication or switch to fluoxetine for a slow taper.
  • Discontinuation syndrome is medically benign and must be distinguished from life-threatening serotonin syndrome or severe substance withdrawal.

  Safety. Discontinuation syndrome is medically benign and must be distinguished from life-threatening serotonin syndrome or severe substance withdrawal.

• Pathophysiology and High-Risk AgentsFirst-line agents like SSRIs and SNRIs vary significantly in their withdrawal risk based on pharmacokinetic half-life:

  • First-line agents like SSRIs and SNRIs vary significantly in their withdrawal risk based on pharmacokinetic half-life:
  • Test writers often try to trick candidates into thinking long half-life drugs cause worse withdrawal because they stay in the body longer. The opposite is true. Short half-life agents cause rapid plasma drop-offs and trigger the most severe withdrawal symptoms.

  Board trap. Test writers often try to trick candidates into thinking long half-life drugs cause worse withdrawal because they stay in the body longer. The opposite is true. Short half-life agents cause rapid plasma drop-offs and trigger the most severe withdrawal symptoms.

• Clinical Presentation and the FINISH MnemonicF: Flu-like symptoms including fatigue, lethargy, malaise, and myalgias.

  • F: Flu-like symptoms including fatigue, lethargy, malaise, and myalgias.
  • I: Insomnia accompanied by vivid, disturbing dreams or nightmares.
  • N: Nausea, vomiting, anorexia, or abdominal cramps.
  • I: Imbalance including dizziness, lightheadedness, vertigo, and gait ataxia.
  • S: Sensory disturbances featuring classic brain zaps, paresthesias, electric shock sensations in the head or limbs, and tinnitus.
  • H: Hyperarousal including anxiety, irritability, agitation, and Headache.

  Safety. While discontinuation symptoms are uncomfortable and distressing to the patient, they are not life-threatening and do not cause autonomic collapse, seizures, or organ failure.

• Tapering and Management Protocols1. Reinstate the antidepressant at the previously effective dose to achieve rapid symptom relief.

  • 1. Reinstate the antidepressant at the previously effective dose to achieve rapid symptom relief.
  • 2. Begin a much slower, gradual taper over several months.
  • 3. Alternatively, switch the patient to an equivalent dose of fluoxetine and allow its long half-life to provide an automatic, smooth taper as it is discontinued.
• Discontinuation Syndrome vs. Serotonin SyndromeThink: Discontinuation syndrome is a benign withdrawal state from stopping a drug; serotonin syndrome is a toxic, life-threatening emergency from drug excess or combination.

  • Think: Discontinuation syndrome is a benign withdrawal state from stopping a drug; serotonin syndrome is a toxic, life-threatening emergency from drug excess or combination.
  • Priority: Reassure and taper for discontinuation syndrome; immediately stop all serotonergic agents and provide emergency supportive care for serotonin syndrome.
  • Boards are testing: Discontinuation features brain zaps, dizziness, and flu-like symptoms; serotonin syndrome features hyperthermia, autonomic instability, diarrhea, and neuromuscular rigidity.
  • Classic distractor: Mistaking early discontinuation anxiety and agitation for acute serotonin syndrome.
• Discontinuation Syndrome vs. Major Depressive RelapseThink: Discontinuation syndrome onset is rapid (24 to 72 hours) with somatic symptoms; depressive relapse onset is gradual (weeks to months) with psychological symptoms.

  • Think: Discontinuation syndrome onset is rapid (24 to 72 hours) with somatic symptoms; depressive relapse onset is gradual (weeks to months) with psychological symptoms.
  • Priority: Reinstate or taper medication for discontinuation syndrome; reassess overall treatment plan and consider switching or augmenting for depressive relapse.
  • Boards are testing: Discontinuation includes unique somatic markers like brain zaps, dizziness, and nausea that rapidly resolve upon restarting the drug; relapse presents with persistent anhedonia, low mood, and SIGECAPS criteria over weeks.
  • Classic distractor: Assuming a patient who feels sick 2 days after stopping an SSRI is experiencing an immediate relapse of severe depression.
• Advanced Bipolar ManagementSymptom Predictors for Mood Stabilizers: Classic euphoric or grandiose mania responds best to lithium. Dysphoric or irritable mania, mixed features, comorbid substance use disorders, or a history of traumatic brain injury responds best to valproate.

  • Symptom Predictors for Mood Stabilizers: Classic euphoric or grandiose mania responds best to lithium. Dysphoric or irritable mania, mixed features, comorbid substance use disorders, or a history of traumatic brain injury responds best to valproate.
  • Suicide Risk Reduction: Lithium and clozapine are the only two psychiatric medications proven to independently reduce suicide risk. Lithium should be retained in the treatment regimen whenever suicidality is present.
  • Lamotrigine Dosing Protocol: Lamotrigine requires no baseline laboratory testing prior to initiation. To prevent Stevens-Johnson syndrome, strictly follow the 6-week titration schedule: 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 100 mg daily for 1 week, then 200 mg daily.
• Psychotropic Monitoring, Laboratory Baselines, and ToxidromesValproate (Divalproex / Depakote):

  • Valproate (Divalproex / Depakote):
  • Baseline Laboratory Workup: Liver function panel (AST, ALT, alkaline phosphatase, bilirubin, albumin, total protein), complete blood count with differential and platelet count, and serum hCG.
  • Therapeutic Range and Level Monitoring: Target serum level is 50 to 120 mcg/mL. Check levels monthly during initial titration, and every 6 to 24 months during stable maintenance.
  • Hepatotoxicity Rules: Transaminase elevations (AST and ALT) occur in 2% to 44% of patients, most commonly during the first 6 months. Discontinue valproate if AST or ALT elevates greater than 2 to 3 times the upper limit of normal.
  • Hematologic Warnings: Thrombocytopenia and neutropenia are major complications; instruct patients to report unusual bruising, petechiae, or bleeding.
  • Boxed Warnings: Neural tube defects (spina bifida), fatal hepatotoxicity, and pancreatitis.
• Medical Mimics and Rule-outsAlways rule out physical medical conditions, lab abnormalities, and substance or medication effects before assigning a primary diagnosis of major depressive disorder or bipolar disorder.

  • Always rule out physical medical conditions, lab abnormalities, and substance or medication effects before assigning a primary diagnosis of major depressive disorder or bipolar disorder.
  • Depressive symptoms caused by a substance or prescribed medication typically remit within 1 month of discontinuing the offending agent.
  • Post-stroke depression occurs frequently in medical inpatients and cerebrovascular populations, with symptom onset typically developing weeks to months following a cerebrovascular accident (CVA).
  • Steroids like prednisone and central nervous system stimulants can induce manic or depressive symptoms. If full manic criteria persist beyond the expected physiological effect of the drug, the diagnosis becomes primary bipolar I disorder.
  • Medical inpatients experience a 15% higher prevalence of major depressive disorder compared to the general population.
  • In neurodegenerative conditions such as Parkinson's disease and Huntington's disease, mood symptoms and depression frequently precede motor impairments.
• Differential Diagnosis and Organic CausesFirst-line clinical priority: Always perform a comprehensive physical evaluation and baseline lab panel (CBC, CMP, TSH, B12, hCG, urine drug screen) to rule out medical mimics before diagnosing a primary psychiatric disorder or initiating psychotropics.

  • First-line clinical priority: Always perform a comprehensive physical evaluation and baseline lab panel (CBC, CMP, TSH, B12, hCG, urine drug screen) to rule out medical mimics before diagnosing a primary psychiatric disorder or initiating psychotropics.
  • Hypothyroidism (elevated TSH) directly mimics unipolar depression, whereas hyperthyroidism or steroid therapy can precipitate manic or hypomanic symptoms. Always assess TSH before diagnosing unipolar depression or escalating antidepressant therapy.
  • Neurologic conditions including stroke (CVA), Multiple Sclerosis, Parkinson's disease, and Huntington's disease directly cause mood alterations. Post-CVA depression typically manifests weeks to months after the vascular event.

  Board trap. Assuming new-onset depressive or manic symptoms in an older adult or medically complex patient are purely psychiatric. Medical inpatients carry a 15% higher risk of major depressive disorder, and general medical comorbidities significantly elevate the 50% to 85% lifetime recurren

  Safety. Hypothyroidism (elevated TSH) directly mimics unipolar depression, whereas hyperthyroidism or steroid therapy can precipitate manic or hypomanic symptoms. Always assess TSH before diagnosing unipolar depression or escalating antidepressant therapy.

• Medication- and Substance-Induced Mood DisordersSubstance or medication-induced depressive disorder requires that mood symptoms develop during or soon after substance exposure, intoxication, or withdrawal, extending beyond expected acute physiological effects. Symptoms usually resolve within 1 month of stopping the substance.

  • Substance or medication-induced depressive disorder requires that mood symptoms develop during or soon after substance exposure, intoxication, or withdrawal, extending beyond expected acute physiological effects. Symptoms usually resolve within 1 month of stopping the substance.
  • Common medication causes of depressive symptoms include beta-blockers, interferon, corticosteroids (prednisone), and central nervous system depressants.
  • If full manic criteria emerge during prednisone or antidepressant therapy and persist at a full syndromal level beyond the expected drug clearance window, the formal diagnosis becomes primary bipolar I disorder.

  Board trap. Confusing drug interactions that elevate lithium toxicity with drugs that cause psychiatric mimics. Ibuprofen, lisinopril, thiazide diuretics, and a GFR under 60 mL/min/1.73 m2 impair renal elimination and trigger lithium toxicity. Conversely, prednisone causes psychiatric side e

  Safety. If full manic criteria emerge during prednisone or antidepressant therapy and persist at a full syndromal level beyond the expected drug clearance window, the formal diagnosis becomes primary bipolar I disorder.

• Bipolar Type II Misdiagnosis vs. Unipolar Major Depressive DisorderThink: Unrecognized hypomanic history versus true unipolar depression.

  • Think: Unrecognized hypomanic history versus true unipolar depression.
  • Priority: Conduct thorough longitudinal screening to uncover past hypomanic blips.
  • Boards are testing: Bipolar II disorder is the most common bipolar spectrum condition misdiagnosed as unipolar MDD because patients seek treatment during depressive phases and rarely report hypomania.
• Suicide Risk AssessmentIndependent Anti-Suicidal Properties: Lithium and clozapine are the only two psychiatric medications proven to independently reduce suicide risk in patients with mood and psychotic disorders.

  • Independent Anti-Suicidal Properties: Lithium and clozapine are the only two psychiatric medications proven to independently reduce suicide risk in patients with mood and psychotic disorders.
  • FDA Black Box Warning: SSRIs carry an FDA boxed warning for increased suicidal ideation in children, adolescents, and young adults up to age 24. This warning specifies an increase in suicidal thoughts, not an increase in completed suicides.
  • Lethality in Overdose: Tricyclic antidepressants such as amitriptyline present a high risk of fatal overdose due to severe cardiac conduction toxicity and arrhythmias, whereas SSRIs and SNRIs have a significantly wider therapeutic window.
  • Emergency Intervention Standards: Electroconvulsive therapy (ECT) is a first-line non-pharmacologic intervention for life-threatening suicidality, severe depression with acute refusal of food or fluids, and severe depression during pregnancy.
  • Bipolar Illness Timing: Patients with bipolar disorder are at the highest risk for suicide attempts during major depressive or mixed episodes, rather than during periods of pure euphoric mania.
  • High-Risk Recurrence Markers: Factors that significantly increase depression recurrence and ongoing suicide risk include prior depressive episodes, early age of onset, co-occurring anxiety disorders, and co-occurring chronic medical conditions like diabetes mellitus.
• Clinical Assessment Sequence and Risk StratificationWhen a patient reports active suicidal ideation, your primary clinical priority is to assess immediate physical safety, determine the presence of a concrete plan and lethal means, and select the appropriate care setting, such as inpatient psychiatric admission versus outpatient s

  • Suicide risk assessment is an essential component of every psychiatric evaluation.
  • In the **DSM-5-TR** framework, suicidal ideation is evaluated under the **SIG E CAPS** diagnostic criteria for **major depressive disorder**.
  • Passive suicidal ideation, such as wishing to go to sleep and not wake up, is the most common presentation in outpatient clinical settings.
  • Active suicidal ideation involves explicit thoughts of self-harm, a specific plan, intent, or accessible lethal means.

  Safety. If a patient in an outpatient setting expresses active suicidal ideation with a intent and access to lethal means, such as a firearm in the home, you must secure immediate safety, arrange emergency evaluation, and never leave the patient unmonitored. Standard outpatient medicatio

• Assessment requires balancing individual risk factors against protective factorsKey protective factors identified in board prep courses include personal resilience, strong social support systems, active religious or spiritual beliefs, and positive therapeutic rapport.

  • Key protective factors identified in board prep courses include personal resilience, strong social support systems, active religious or spiritual beliefs, and positive therapeutic rapport.
• Pharmacotherapy and Safety Pearls**Lithium** is a foundational mood stabilizer that possesses independent anti-suicidal properties.

  • **Lithium** is a foundational mood stabilizer that possesses independent anti-suicidal properties.
  • In patients with **bipolar disorder** or severe recurrent **major depressive disorder**, retaining or initiating **lithium** provides documented protection against suicide attempts and completed suicide.
  • **Clozapine** is the second agent with demonstrated independent efficacy in reducing suicidal behavior, specifically in patients with **schizophrenia** or **schizoaffective disorder**.
  • **Board Trap**: Test writers often attempt to trick test-takers into choosing **amitriptyline** or other tricyclic antidepressants for depressed patients with chronic pain or insomnia.

  Board trap. Test writers often attempt to trick test-takers into choosing amitriptyline or other tricyclic antidepressants for depressed patients with chronic pain or insomnia. Remember that tricyclic antidepressants carry a high risk of lethal cardiac toxicity in overdose. Prescribing a 30-

  Safety. SSRIs carry an explicit FDA boxed warning for individuals up to age 24 regarding increased suicidal ideation during the initial weeks of treatment. When initiating an SSRI in adolescents or young adults, counsel the patient and family regarding early monitoring, weekly check-ins

• Bipolar Disorder and Special PopulationsIn patients with **bipolar disorder**, suicide risk is unevenly distributed across phase presentations.

  • In patients with **bipolar disorder**, suicide risk is unevenly distributed across phase presentations.
  • **Board Trap**: A common misconception is that patients with **bipolar disorder** are most likely to attempt suicide during severe manic episodes due to impulsivity.
  • Board exams specifically test the fact that suicide attempts occur most frequently during depressed phases or mixed states, where profound despair coexists with elevated psychomotor energy.

  Board trap. A common misconception is that patients with bipolar disorder are most likely to attempt suicide during severe manic episodes due to impulsivity. Board exams specifically test the fact that suicide attempts occur most frequently during depressed phases or mixed states, where prof

• An overdose of which of the following medications is most likely to be fatal?Pause. Answer: A

  • Pause. Answer: A
  • Why the Other Choices Are Wrong:
  • A: Correct option.
  • B: Incorrect because duloxetine, an SNRI, has a significantly wider therapeutic index and is substantially less cardiotoxic in overdose.
  • C: Incorrect because fluoxetine, an SSRI, is relatively safe in acute overdose when ingested as a single agent.
  • D: Incorrect because while bupropion lowers the seizure threshold at high doses, it lacks the severe fatal cardiotoxicity associated with tricyclic antidepressant overdoses.
• Peripartum vs Baby BluesBaby blues is a mild, self-limiting mood disturbance peaking 3 to 5 days postpartum and resolving within 10 to 14 days (2 weeks), affecting up to 80% of new mothers without causing severe functional disruption.

  • Baby blues is a mild, self-limiting mood disturbance peaking 3 to 5 days postpartum and resolving within 10 to 14 days (2 weeks), affecting up to 80% of new mothers without causing severe functional disruption.
  • Major depressive disorder with peripartum onset requires meeting full DSM-5-TR MDD criteria of at least 5 SIGECAPS symptoms for at least 2 weeks, with symptom onset occurring during pregnancy or within the first 4 weeks postpartum.
  • Postpartum psychosis is a psychiatric emergency occurring in 1 to 2 per 1,000 deliveries, presenting rapidly within 2 to 3 weeks postpartum with mania, confusion, hallucinations, and infant-focused delusions.
  • First-line treatment for mild to moderate peripartum depression is evidence-based psychotherapy, specifically interpersonal psychotherapy (IPT) or cognitive behavioral therapy (CBT).
  • First-line pharmacotherapy for moderate to severe peripartum depression includes sertraline or citalopram, with sertraline preferred during lactation due to low excretion into breast milk (Hale Category L2).
  • Lithium is contraindicated during lactation (Hale Category L4) due to high infant blood levels, risk of toxicity, and fluid balance disruptions.

  Board trap. Do not choose watchful waiting or "no treatment" for a pregnant patient with moderate depression score, as untreated depression poses serious risks of preterm labor, low birth weight, and poor maternal bonding.

  Safety. Lithium is contraindicated during lactation (Hale Category L4) due to high infant blood levels, risk of toxicity, and fluid balance disruptions.

• Baby BluesSupportive care, reassurance, education, and assistance with sleep hygiene. Psychotropics are not indicated.

  • What it is: Transient, non-pathological emotional lability following delivery.
  • Timeline: Onset within 2 to 3 days postpartum, peaking at day 3 to 5, and resolving spontaneously within 10 to 14 days.
  • Must-know features: Characterized by tearfulness, mild anxiety, irritability, and mood swings. Daily functioning remains intact.
  • Supportive care, reassurance, education, and assistance with sleep hygiene. Psychotropics are not indicated.
• Major Depressive Disorder with Peripartum OnsetNon-pharmacologic approaches like IPT or CBT for mild to moderate severity. SSRIs such as sertraline or citalopram when pharmacotherapy is necessary.

  • What it is: Major depressive episode occurring during gestation or in the early postpartum period.
  • Timeline: DSM-5-TR specifier requires symptom onset during pregnancy or within 4 weeks after childbirth, though clinical presentation can occur throughout the first postpartum year. Symptoms must last at least 2 weeks.
  • Must-know features: Requires 5 or more SIGECAPS criteria, including mandatory depressed mood or anhedonia, accompanied by guilt, sleep disturbance, or fatigue.
  • Non-pharmacologic approaches like IPT or CBT for mild to moderate severity. SSRIs such as sertraline or citalopram when pharmacotherapy is necessary.
  • Maternal depression must be treated; leaving mood disorders unmanaged during pregnancy increases fetal and maternal morbidity.

  Safety. Maternal depression must be treated; leaving mood disorders unmanaged during pregnancy increases fetal and maternal morbidity.

• Postpartum PsychosisWhat it is: Severe, acute psychotic mood episode, most commonly an expression of underlying bipolar spectrum disorder.

  • What it is: Severe, acute psychotic mood episode, most commonly an expression of underlying bipolar spectrum disorder.
  • Timeline: Onset is typically abrupt, occurring within 2 to 3 weeks after delivery.
  • Must-know features: Depersonalization, severe insomnia, mood lability, auditory hallucinations, and delusional beliefs regarding the infant (such as baby being possessed or defective).
  • Requires immediate psychiatric evaluation and emergency inpatient hospitalization due to extreme risk of infanticide or maternal suicide.

  Safety. Requires immediate psychiatric evaluation and emergency inpatient hospitalization due to extreme risk of infanticide or maternal suicide.

• Baby Blues vs. Peripartum DepressionThink: Blues is brief tearfulness that resolves by two weeks; peripartum depression is persistent functional impairment lasting beyond two weeks.

  • Think: Blues is brief tearfulness that resolves by two weeks; peripartum depression is persistent functional impairment lasting beyond two weeks.
  • Priority: Monitor duration. If mood symptoms extend past 14 days, re-screen using the PHQ-9 or Edinburgh Postnatal Depression Scale to diagnose peripartum depression.
  • Boards are testing: Recognizing the 2-week cutoff where normal transitional blues becomes a treatable clinical depression.
• Obsessive Intrusive Thoughts vs. Postpartum PsychosisThink: Intrusive harm thoughts in postpartum OCD/depression are egodystonic and cause extreme maternal distress; psychotic delusions are egosyntonic beliefs that lead to unsafe actions.

  • Think: Intrusive harm thoughts in postpartum OCD/depression are egodystonic and cause extreme maternal distress; psychotic delusions are egosyntonic beliefs that lead to unsafe actions.
  • Priority: Assess reality testing and intent. Egodystonic fear of harming the baby requires anxiety/depression management; egosyntonic delusional beliefs require immediate emergency admission.
  • Mistaking severe maternal anxiety and intrusive fears for psychosis, leading to inappropriate involuntary commitment or unnecessary medication changes.

  Board trap. Mistaking severe maternal anxiety and intrusive fears for psychosis, leading to inappropriate involuntary commitment or unnecessary medication changes.

• Prescribing and Safety PearlsFirst-line in pregnancy: Sertraline and citalopram have extensive safety data demonstrating low overall teratogenic risk.

  • First-line in pregnancy: Sertraline and citalopram have extensive safety data demonstrating low overall teratogenic risk.
  • First-line in lactation: Sertraline is the preferred SSRI during breastfeeding due to minimal drug levels transfer into human breast milk.
  • Lithium carries a Hale Category L4 rating in lactating mothers because infant renal clearance is immature, creating a high risk of infant lithium toxicity and severe dehydration.

  Safety. Lithium carries a Hale Category L4 rating in lactating mothers because infant renal clearance is immature, creating a high risk of infant lithium toxicity and severe dehydration.

• Safety and Risk ManagementPostpartum psychosis is an absolute psychiatric emergency. Delusions regarding infant contamination or possession create extreme risk for infanticide or suicide, requiring immediate inpatient psychiatric admission and continuous observation.

  • Postpartum psychosis is an absolute psychiatric emergency. Delusions regarding infant contamination or possession create extreme risk for infanticide or suicide, requiring immediate inpatient psychiatric admission and continuous observation.
  • Avoid assuming psychotropic medications or ECT cannot be used in pregnant or lactating patients. Untreated maternal depression carries significant risks of low birth weight, premature delivery, and impaired bonding.

  Board trap. Avoid misdiagnosing postpartum psychosis as brief "postpartum blues." Postpartum blues are mild, self-limiting, and resolve within 10 to 14 days without functional impairment or psychotic features, whereas psychosis requires immediate antipsychotic or mood stabilizer intervention

  Safety. Postpartum psychosis is an absolute psychiatric emergency. Delusions regarding infant contamination or possession create extreme risk for infanticide or suicide, requiring immediate inpatient psychiatric admission and continuous observation.

• Pharmacotherapy and InterventionsInterpersonal psychotherapy (IPT) is the preferred non-pharmacologic treatment for mild to moderate peripartum depression.

  • Interpersonal psychotherapy (IPT) is the preferred non-pharmacologic treatment for mild to moderate peripartum depression.
  • When pharmacotherapy is necessary for moderate to severe peripartum depression, sertraline or citalopram are well-supported choices.
  • Lithium is classified as Hale's Lactation Risk Category L4. It passes directly into breast milk, creating severe risks of infant dehydration, electrolyte disturbance, and renal toxicity.
  • Electroconvulsive therapy (ECT) remains one of the safest and fastest treatments for pregnant patients presenting with severe psychotic depression, acute mania, or active suicidality.
  • Brexanolone is administered as a 60-hour intravenous infusion under continuous pulse oximetry monitoring due to risks of sudden sedation and loss of consciousness. Zuranolone provides a 14-day oral course for postpartum depression.

  Safety. Lithium is classified as Hale's Lactation Risk Category L4. It passes directly into breast milk, creating severe risks of infant dehydration, electrolyte disturbance, and renal toxicity.

• Pediatric Mood PresentationIn children and adolescents with major depressive disorder, core mood disruption frequently manifests as irritability rather than depressed mood, described clinically as a "mad at the world" outlook.

  • In children and adolescents with major depressive disorder, core mood disruption frequently manifests as irritability rather than depressed mood, described clinically as a "mad at the world" outlook.
  • Pediatric physical criteria for major depressive disorder includes a failure to make expected weight gain rather than classic weight loss or weight gain.
  • Diagnostic timelines for persistent depressive disorder (dysthymia) and cyclothymic disorder are shortened to 1 year in children and adolescents, compared to 2 years in adults.
  • Maximum allowable symptom-free duration for both persistent depressive disorder and cyclothymic disorder is 2 months across all age groups.
  • The incidence of bipolar disorder in children and adolescents is 1%, where mania or hypomania presents as developmental giddiness, happiness, or silliness distinctly elevated above baseline.
  • All SSRIs carry an FDA black box warning for increased suicidal ideation in children, adolescents, and young adults up to age 24.
• Clinical Features of Pediatric DepressionWhen evaluating mood disorders in pediatric populations, clinicians must adapt adult DSM-5-TR criteria to developmental equivalents.

  • When evaluating mood disorders in pediatric populations, clinicians must adapt adult DSM-5-TR criteria to developmental equivalents.
  • In children and adolescents experiencing a major depressive episode, depressed mood often presents as persistent **irritability**, angry outbursts, or a pervasive hostility toward peers, teachers, and family.
  • Vegetative signs also differ in growing youth.
  • While adults demonstrate explicit weight loss or weight gain, pediatric patients frequently manifest appetite changes as a **failure to make expected weight gain** for their growth curve.

  Board trap. Do not misdiagnose a child presenting with chronic irritability as having oppositional defiant disorder or conduct disorder without screening for underlying mood pathology. Chronic irritability is a primary depression equivalent in youth. Additionally, do not fail pediatric board

• Pediatric Bipolar and Cyclothymic PresentationsBipolar disorder has an estimated incidence of 1% in children and adolescents. Diagnosing manic or hypomanic episodes in pediatric patients requires distinguishing normal childhood energy from pathological mood elevation.

  • Bipolar disorder has an estimated incidence of 1% in children and adolescents. Diagnosing manic or hypomanic episodes in pediatric patients requires distinguishing normal childhood energy from pathological mood elevation.
  • Never assume pediatric mania requires adult-style grandiosity or financial spending sprees. Look for cyclic, out-of-context silliness, decreased need for sleep, and marked surges in activity that disrupt school or family life.

  Board trap. Never assume pediatric mania requires adult-style grandiosity or financial spending sprees. Look for cyclic, out-of-context silliness, decreased need for sleep, and marked surges in activity that disrupt school or family life.

• Pharmacotherapy and Safety WarningsFor mild to moderate pediatric depression, evidence-based psychotherapy such as cognitive behavioral therapy (CBT) or interpersonal psychotherapy (IPT) is the primary first-line intervention. For severe depression, combining an SSRI with psychotherapy represents the gold standard

  • When selecting pharmacotherapy for pediatric and young adult mood disorders, safety monitoring is the top priority.
  • Test writers frequently emphasize that this warning reflects increased suicidal thoughts, not an increase in completed suicides.
  • Close clinical monitoring is required during the initial 4 to 8 weeks of therapy.
  • **First-line:** For mild to moderate pediatric depression, evidence-based psychotherapy such as **cognitive behavioral therapy** (CBT) or **interpersonal psychotherapy** (IPT) is the primary first-line intervention.

  Safety. All antidepressant medications, including SSRIs like fluoxetine and sertraline, carry a prominent FDA black box warning for an increased risk of suicidal ideation and suicidal behaviors in children, adolescents, and young adults up to age 24. Test writers frequently emphasize tha

• B) A 45-year-old man with anorgasmia who is an occasional marijuana userPause. Answer: C

  • Pause. Answer: C
  • Why It Is Correct:
  • Why the Other Choices Are Wrong:
  • A: Older adults taking multiple medications should avoid fluoxetine due to its potent inhibition of CYP2D6 and CYP3A4 isoenzymes, which causes significant drug interactions, and its propensity to worsen agitation.
  • B: Fluoxetine and other SSRIs frequently cause sexual dysfunction, including anorgasmia and delayed ejaculation, making it a poor choice for a patient already experiencing anorgasmia.
  • D: Fluoxetine commonly causes anorexia and weight loss as initial side effects, which would exacerbate this patient's existing decreased appetite.
• C) Initiate therapy with a therapeutic dose of citalopramPause. Answer: A

  • Pause. Answer: A
  • Why It Is Correct:
  • Why the Other Choices Are Wrong:
  • B: Psychotherapy, specifically interpersonal therapy or CBT, is an effective and appropriate first-line treatment for mild to moderate depression during pregnancy.
  • C: Citalopram is an acceptable SSRI option during pregnancy when benefits outweigh risks after patient education and informed consent.
  • D: Sertraline is one of the most widely studied and preferred SSRIs during pregnancy and lactation due to low fetal and breastmilk transfer.
• Board Trap: Bereavement SpecifierPsychotherapy such as cognitive behavioral therapy or interpersonal therapy alone is effective for mild to moderate depression, while severe depression requires pharmacotherapy with an SSRI such as sertraline or fluoxetine, or combination therapy.

  • Major depressive disorder requires five or more SIGECAPS symptoms present nearly every day for at least two weeks, with at least one symptom being depressed mood or anhedonia.
  • Altered mood associated with bereavement is not a DSM-5-TR diagnostic criterion for a major depressive episode.
  • Normal grief follows a major loss, but if the patient meets full diagnostic criteria with five or more symptoms for two or more weeks causing functional impairment, a diagnosis of major depressive disorder is made concurrently with bereavement.
  • Adjustment disorder with depressed mood occurs within three months of an identifiable stressor and causes marked emotional distress or functional impairment, but fails to meet the five-symptom threshold for major depressive disorder.
  • Passive suicidal ideation without a plan is the most common form of suicidal thought in depression, and suicide risk must be evaluated at every visit. Lithium and clozapine are the only two psychotropic medications with proven independent anti-suicide effects.
  • Psychotherapy such as cognitive behavioral therapy or interpersonal therapy alone is effective for mild to moderate depression, while severe depression requires pharmacotherapy with an SSRI such as sertraline or fluoxetine, or combination therapy.

  Board trap. Altered mood associated with bereavement is not a DSM-5-TR diagnostic criterion for a major depressive episode.

  Safety. Passive suicidal ideation without a plan is the most common form of suicidal thought in depression, and suicide risk must be evaluated at every visit. Lithium and clozapine are the only two psychotropic medications with proven independent anti-suicide effects.

• Differential DiagnosticsPersistent depressive disorder: Requires a depressed mood plus at least two depressive symptoms present for at least two years in adults, or one year in children and adolescents, without being symptom-free for more than two months.

  • Persistent depressive disorder: Requires a depressed mood plus at least two depressive symptoms present for at least two years in adults, or one year in children and adolescents, without being symptom-free for more than two months.

  Board trap. Test writers often present a patient experiencing recent spousal death or significant loss and ask if depression can be diagnosed. If five or more SIGECAPS criteria are present for two or more weeks, diagnose major depressive disorder. Do not assume grief protects against depress

• Signposted Exam StrategySelect cognitive behavioral therapy or interpersonal therapy for mild to moderate depression, especially in pregnant or lactating patients where medication avoidance is preferred. Select an SSRI or combination therapy for severe depression.

  • Selecting altered mood associated with bereavement as a formal diagnostic criterion for major depression. Bereavement is a clinical context, not a criterion.
  • Assess for suicide at every encounter. In patients taking SSRIs, a boxed warning exists for increased suicidal ideation in adolescents and young adults up to age 24.
  • Select cognitive behavioral therapy or interpersonal therapy for mild to moderate depression, especially in pregnant or lactating patients where medication avoidance is preferred. Select an SSRI or combination therapy for severe depression.

  Board trap. Selecting altered mood associated with bereavement as a formal diagnostic criterion for major depression. Bereavement is a clinical context, not a criterion.

  Safety. Assess for suicide at every encounter. In patients taking SSRIs, a boxed warning exists for increased suicidal ideation in adolescents and young adults up to age 24.

• Sample Question 17: Developmental OnsetMajor depressive disorder mean age of onset is 20 to 35 years, with prevalence in adults aged 18 to 29 years being 3 times higher than in adults over 60 years.

  • Major depressive disorder mean age of onset is 20 to 35 years, with prevalence in adults aged 18 to 29 years being 3 times higher than in adults over 60 years.
  • Bipolar disorder mean age of onset is 21 to 24 years, with a 1% incidence in children and adolescents.
  • In children and adolescents, the core mood equivalent for major depressive disorder is irritability, and appetite changes may present as failure to make expected weight gain.
  • Diagnostic duration criteria for persistent depressive disorder and cyclothymic disorder require 2 years in adults, but only 1 year in children and adolescents.
  • All SSRIs carry an FDA black box warning for increased suicidal ideation in children, adolescents, and young adults up to 24 years of age.
  • Peripartum onset specifier is defined as mood symptom onset during pregnancy or within 4 weeks following delivery; lithium is classified as Hale Category L4 (hazardous) during breastfeeding, whereas most SSRIs are Category L2.
• Safety AlertSuicide Risk: The risk of suicide in bipolar disorder and major depressive disorder is highest during major depressive episodes or mixed states, not during pure euphoric mania. Lithium and clozapine are the only two psychotropics with proven independent anti-suicidal properties.

  • Suicide Risk: The risk of suicide in bipolar disorder and major depressive disorder is highest during major depressive episodes or mixed states, not during pure euphoric mania. Lithium and clozapine are the only two psychotropics with proven independent anti-suicidal properties.
  • Pediatric Black Box Warning: All SSRIs require close surveillance for emergent suicidal ideation in patients up to 24 years of age, particularly during the initial 4 to 6 weeks of treatment or after dosage escalations.
  • Geriatric Prescribing: Citalopram dosing must be restricted to a maximum of 20 mg daily in adults over 60 years of age due to dose-dependent QTc interval prolongation.